<?xml version='1.0' encoding='UTF-8'?>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Alzheimers Res Ther</journal-id><journal-id journal-id-type="iso-abbrev">Alzheimers Res Ther</journal-id><journal-id journal-id-type="pmc-domain-id">943</journal-id><journal-id journal-id-type="pmc-domain">alzreth</journal-id><journal-title-group><journal-title>Alzheimer's Research &amp; Therapy</journal-title></journal-title-group><issn pub-type="epub">1758-9193</issn><publisher><publisher-name>BMC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11917016</article-id><article-id pub-id-type="pmcid-ver">PMC11917016.1</article-id><article-id pub-id-type="pmcaid">11917016</article-id><article-id pub-id-type="pmcaiid">11917016</article-id><article-id pub-id-type="pmid">40098158</article-id><article-id pub-id-type="doi">10.1186/s13195-025-01707-9</article-id><article-id pub-id-type="publisher-id">1707</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Perivascular space and white matter hyperintensities in Alzheimer’s disease: associations with disease progression and cognitive function</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Schirge</surname><given-names initials="PM">Philine Marie</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Perneczky</surname><given-names initials="R">Robert</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref><xref ref-type="aff" rid="Aff6">6</xref><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Taoka</surname><given-names initials="T">Toshiaki</given-names></name><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ruiz-Rizzo</surname><given-names initials="AL">Adriana L.</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ersoezlue</surname><given-names initials="E">Ersin</given-names></name><xref ref-type="aff" rid="Aff10">10</xref><xref ref-type="aff" rid="Aff11">11</xref><xref ref-type="aff" rid="Aff12">12</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Forbrig</surname><given-names initials="R">Robert</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Guersel</surname><given-names initials="S">Selim</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kurz</surname><given-names initials="C">Carolin</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Brendel</surname><given-names initials="M">Matthias</given-names></name><xref ref-type="aff" rid="Aff6">6</xref><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hellmann-Regen</surname><given-names initials="J">Julian</given-names></name><xref ref-type="aff" rid="Aff10">10</xref><xref ref-type="aff" rid="Aff11">11</xref><xref ref-type="aff" rid="Aff12">12</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Priller</surname><given-names initials="J">Josef</given-names></name><xref ref-type="aff" rid="Aff10">10</xref><xref ref-type="aff" rid="Aff14">14</xref><xref ref-type="aff" rid="Aff15">15</xref><xref ref-type="aff" rid="Aff16">16</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Schneider</surname><given-names initials="A">Anja</given-names></name><xref ref-type="aff" rid="Aff17">17</xref><xref ref-type="aff" rid="Aff18">18</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Jessen</surname><given-names initials="F">Frank</given-names></name><xref ref-type="aff" rid="Aff17">17</xref><xref ref-type="aff" rid="Aff19">19</xref><xref ref-type="aff" rid="Aff20">20</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Düzel</surname><given-names initials="E">Emrah</given-names></name><xref ref-type="aff" rid="Aff21">21</xref><xref ref-type="aff" rid="Aff22">22</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Buerger</surname><given-names initials="K">Katharina</given-names></name><xref ref-type="aff" rid="Aff4">4</xref><xref ref-type="aff" rid="Aff23">23</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Teipel</surname><given-names initials="S">Stefan</given-names></name><xref ref-type="aff" rid="Aff24">24</xref><xref ref-type="aff" rid="Aff25">25</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Laske</surname><given-names initials="C">Christoph</given-names></name><xref ref-type="aff" rid="Aff26">26</xref><xref ref-type="aff" rid="Aff27">27</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Peters</surname><given-names initials="O">Oliver</given-names></name><xref ref-type="aff" rid="Aff10">10</xref><xref ref-type="aff" rid="Aff13">13</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Spruth</surname><given-names initials="E">Eike</given-names></name><xref ref-type="aff" rid="Aff10">10</xref><xref ref-type="aff" rid="Aff14">14</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Fliessbach</surname><given-names initials="K">Klaus</given-names></name><xref ref-type="aff" rid="Aff17">17</xref><xref ref-type="aff" rid="Aff18">18</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Rostamzadeh</surname><given-names initials="A">Ayda</given-names></name><xref ref-type="aff" rid="Aff19">19</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Glanz</surname><given-names initials="W">Wenzel</given-names></name><xref ref-type="aff" rid="Aff21">21</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Janowitz</surname><given-names initials="D">Daniel</given-names></name><xref ref-type="aff" rid="Aff23">23</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kilimann</surname><given-names initials="I">Ingo</given-names></name><xref ref-type="aff" rid="Aff24">24</xref><xref ref-type="aff" rid="Aff25">25</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sodenkamp</surname><given-names initials="S">Sebastian</given-names></name><xref ref-type="aff" rid="Aff26">26</xref><xref ref-type="aff" rid="Aff28">28</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ewers</surname><given-names initials="M">Michael</given-names></name><xref ref-type="aff" rid="Aff4">4</xref><xref ref-type="aff" rid="Aff23">23</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Rauchmann</surname><given-names initials="BS">Boris-Stephan</given-names></name><address><email>boris.rauchmann@med.uni-muenchen.de</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref><xref ref-type="aff" rid="Aff29">29</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05591te55</institution-id><institution-id institution-id-type="GRID">grid.5252.0</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 973X</institution-id><institution>Institute of Neuroradiology, </institution><institution>LMU Hospital, LMU Munich, </institution></institution-wrap>Munich, Germany </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05591te55</institution-id><institution-id institution-id-type="GRID">grid.5252.0</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 973X</institution-id><institution>Department of Psychiatry and Psychotherapy, </institution><institution>LMU Hospital, LMU Munich, </institution></institution-wrap>Munich, Germany </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05krs5044</institution-id><institution-id institution-id-type="GRID">grid.11835.3e</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 9262</institution-id><institution>Sheffield Institute for Translational Neuroscience (SITraN), University of Sheffield, </institution></institution-wrap>Sheffield, UK </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/043j0f473</institution-id><institution-id institution-id-type="GRID">grid.424247.3</institution-id><institution-id institution-id-type="ISNI">0000 0004 0438 0426</institution-id><institution>German Center for Neurodegenerative Diseases (DZNE) Munich, </institution></institution-wrap>Munich, Germany </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/035rzkx15</institution-id><institution-id institution-id-type="GRID">grid.275559.9</institution-id><institution-id institution-id-type="ISNI">0000 0000 8517 6224</institution-id><institution>Department of Neurology, </institution><institution>Jena University Hospital, </institution></institution-wrap>Jena, Germany </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/025z3z560</institution-id><institution-id institution-id-type="GRID">grid.452617.3</institution-id><institution>Munich Cluster for Systems Neurology (SyNergy), </institution></institution-wrap>Munich, Germany </aff><aff id="Aff7"><label>7</label>Ageing Epidemiology (AGE) Research Unit, School of Public HealthImperial College London, London, UK </aff><aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04chrp450</institution-id><institution-id institution-id-type="GRID">grid.27476.30</institution-id><institution-id institution-id-type="ISNI">0000 0001 0943 978X</institution-id><institution>Department of Innovative Biomedical Visualization (iBMV), </institution><institution>Graduate School of Medicine, Nagoya University, </institution></institution-wrap>Nagoya, Japan </aff><aff id="Aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05591te55</institution-id><institution-id institution-id-type="GRID">grid.5252.0</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 973X</institution-id><institution>Department of Nuclear Medicine, </institution><institution>Ludwig Maximilian University Hospital, Ludwig Maximilian University of Munich, </institution></institution-wrap>Munich, Germany </aff><aff id="Aff10"><label>10</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/043j0f473</institution-id><institution-id institution-id-type="GRID">grid.424247.3</institution-id><institution-id institution-id-type="ISNI">0000 0004 0438 0426</institution-id><institution>German Center for Neurodegenerative Diseases (DZNE), </institution></institution-wrap>Berlin, Germany </aff><aff id="Aff11"><label>11</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/001w7jn25</institution-id><institution-id institution-id-type="GRID">grid.6363.0</institution-id><institution-id institution-id-type="ISNI">0000 0001 2218 4662</institution-id><institution>Department of Psychiatry and Neurosciences, </institution><institution>Charité Universitätsmedizin Berlin, </institution></institution-wrap>Berlin, Germany </aff><aff id="Aff12"><label>12</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/001w7jn25</institution-id><institution-id institution-id-type="GRID">grid.6363.0</institution-id><institution-id institution-id-type="ISNI">0000 0001 2218 4662</institution-id><institution>ECRC Experimental and Clinical Research Center, Charité– Universitätsmedizin Berlin, </institution></institution-wrap>Berlin, Germany </aff><aff id="Aff13"><label>13</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/001w7jn25</institution-id><institution-id institution-id-type="GRID">grid.6363.0</institution-id><institution-id institution-id-type="ISNI">0000 0001 2218 4662</institution-id><institution>Charité– Universitätsmedizin Berlin, Corporate Member of Freie Universität BerlinHumboldt-Universität zu Berlin-Institute of Psychiatry and Psychotherapy, </institution></institution-wrap>Berlin, Germany </aff><aff id="Aff14"><label>14</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/001w7jn25</institution-id><institution-id institution-id-type="GRID">grid.6363.0</institution-id><institution-id institution-id-type="ISNI">0000 0001 2218 4662</institution-id><institution>Department of Psychiatry and Psychotherapy, </institution><institution>Charité, </institution></institution-wrap>Charitéplatz 1, 10117 Berlin, Germany </aff><aff id="Aff15"><label>15</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02kkvpp62</institution-id><institution-id institution-id-type="GRID">grid.6936.a</institution-id><institution-id institution-id-type="ISNI">0000 0001 2322 2966</institution-id><institution>Department of Psychiatry, </institution><institution>School of Medicine, Technical University of Munich, </institution></institution-wrap>Munich, Germany </aff><aff id="Aff16"><label>16</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01nrxwf90</institution-id><institution-id institution-id-type="GRID">grid.4305.2</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 7988</institution-id><institution>University of Edinburgh, UK DRI, </institution></institution-wrap>Edinburgh, UK </aff><aff id="Aff17"><label>17</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/043j0f473</institution-id><institution-id institution-id-type="GRID">grid.424247.3</institution-id><institution-id institution-id-type="ISNI">0000 0004 0438 0426</institution-id><institution>German Center for Neurodegenerative Diseases (DZNE)Venusberg-Campus, </institution></institution-wrap>Bonn, Germany </aff><aff id="Aff18"><label>18</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01xnwqx93</institution-id><institution-id institution-id-type="GRID">grid.15090.3d</institution-id><institution-id institution-id-type="ISNI">0000 0000 8786 803X</institution-id><institution>Department of Old Age Psychiatry and Cognitive Disorders, </institution><institution>University Hospital Bonn, </institution></institution-wrap>Bonn, Germany </aff><aff id="Aff19"><label>19</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00rcxh774</institution-id><institution-id institution-id-type="GRID">grid.6190.e</institution-id><institution-id institution-id-type="ISNI">0000 0000 8580 3777</institution-id><institution>Department of Psychiatry, </institution><institution>University of Cologne, Medical Faculty, </institution></institution-wrap>Kerpener Strasse 62, 50924 Cologne, Germany </aff><aff id="Aff20"><label>20</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00rcxh774</institution-id><institution-id institution-id-type="GRID">grid.6190.e</institution-id><institution-id institution-id-type="ISNI">0000 0000 8580 3777</institution-id><institution>Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases, University of Cologne, </institution></institution-wrap>Cologne, Germany </aff><aff id="Aff21"><label>21</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/043j0f473</institution-id><institution-id institution-id-type="GRID">grid.424247.3</institution-id><institution-id institution-id-type="ISNI">0000 0004 0438 0426</institution-id><institution>German Center for Neurodegenerative Diseases (DZNE), </institution></institution-wrap>Magdeburg, Germany </aff><aff id="Aff22"><label>22</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00ggpsq73</institution-id><institution-id institution-id-type="GRID">grid.5807.a</institution-id><institution-id institution-id-type="ISNI">0000 0001 1018 4307</institution-id><institution>Institute of Cognitive Neurology and Dementia Research (IKND), Otto-von-Guericke University, </institution></institution-wrap>Magdeburg, Germany </aff><aff id="Aff23"><label>23</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05591te55</institution-id><institution-id institution-id-type="GRID">grid.5252.0</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 973X</institution-id><institution>Institute for Stroke and Dementia Research (ISD), Ludwig Maximilian University Hospital, Ludwig Maximilian University, </institution></institution-wrap>Munich, Germany </aff><aff id="Aff24"><label>24</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/043j0f473</institution-id><institution-id institution-id-type="GRID">grid.424247.3</institution-id><institution-id institution-id-type="ISNI">0000 0004 0438 0426</institution-id><institution>German Center for Neurodegenerative Diseases (DZNE), </institution></institution-wrap>Rostock, Germany </aff><aff id="Aff25"><label>25</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03zdwsf69</institution-id><institution-id institution-id-type="GRID">grid.10493.3f</institution-id><institution-id institution-id-type="ISNI">0000 0001 2185 8338</institution-id><institution>Department of Psychosomatic Medicine, </institution><institution>Rostock University Medical Center, </institution></institution-wrap>Gehlsheimer Str. 20, Rostock, Germany </aff><aff id="Aff26"><label>26</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/043j0f473</institution-id><institution-id institution-id-type="GRID">grid.424247.3</institution-id><institution-id institution-id-type="ISNI">0000 0004 0438 0426</institution-id><institution>German Center for Neurodegenerative Diseases (DZNE), </institution></institution-wrap>Tübingen, Germany </aff><aff id="Aff27"><label>27</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04zzwzx41</institution-id><institution-id institution-id-type="GRID">grid.428620.a</institution-id><institution>Department of Psychiatry and Psychotherapy, Section for Dementia Research, </institution><institution>Hertie Institute for Clinical Brain Research and University of Tübingen, </institution></institution-wrap>Tübingen, Germany </aff><aff id="Aff28"><label>28</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03a1kwz48</institution-id><institution-id institution-id-type="GRID">grid.10392.39</institution-id><institution-id institution-id-type="ISNI">0000 0001 2190 1447</institution-id><institution>Department of Psychiatry and Psychotherapy, </institution><institution>University of Tübingen, </institution></institution-wrap>Tübingen, Germany </aff><aff id="Aff29"><label>29</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05591te55</institution-id><institution-id institution-id-type="GRID">grid.5252.0</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 973X</institution-id><institution>Institute of Neuroradiology, University Hospital, </institution><institution>LMU Munich, Marchioninistraße 15, </institution></institution-wrap>81377 München, Germany </aff></contrib-group><pub-date pub-type="epub"><day>18</day><month>3</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>17</volume><issue-id pub-id-type="pmc-issue-id">478170</issue-id><elocation-id>62</elocation-id><history><date date-type="received"><day>20</day><month>11</month><year>2024</year></date><date date-type="accepted"><day>26</day><month>2</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>18</day><month>03</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>18</day><month>03</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-03-19 10:25:21.580"><day>19</day><month>03</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>© The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="13195_2025_Article_1707.pdf"/><abstract id="Abs1"><sec><title>Background</title><p id="Par1">Alzheimer’s disease (AD) is the leading cause of dementia, characterized by the accumulation of amyloid-beta (Aβ) and neurofibrillary tangles. Recent studies emphasize the role of vascular factors, including the glymphatic system, in AD pathogenesis, particularly in Aβ clearance. The diffusion tensor image analysis along the perivascular space (DTI-ALPS; ALPS-Index) has emerged as a novel, non-invasive method to evaluate the glymphatic system in vivo, showing glymphatic insufficiency in AD. This study aimed to investigate alterations in the function of the glymphatic system in individuals with AD versus healthy controls (HC), and to explore its association with Aβ, cerebrovascular disease (CVD), white matter hyperintensities (WMH), and cognitive function.</p></sec><sec><title>Methods</title><p id="Par2">DTI MRI data from three independent study cohorts (ActiGliA: AD <italic toggle="yes">n</italic> = 16, Controls <italic toggle="yes">n</italic> = 18; DELCODE: AD <italic toggle="yes">n</italic> = 54, Controls <italic toggle="yes">n</italic> = 67; ADNI: AD <italic toggle="yes">n</italic> = 43, Controls <italic toggle="yes">n</italic> = 49) were used to evaluate the perivascular space (PVS) integrity; a potential biomarker for glymphatic activity. The DTI-Along the Perivascular Space technique was used to measure water diffusion along PVS providing an index to assess the efficiency of the glymphatic system’s waste clearance function. WMH load was quantified in FLAIR MRI using the lesion segmentation tool. We quantified WMHs volume within our defined region of interest (ROI) and excluded participants with any WMHs to avoid confounding the ALPS-Index. Associations with cerebrospinal fluid (CSF) AD hallmark biomarkers, cognitive performance (MMSE) and clinical severity (CDR) were assessed.</p></sec><sec><title>Results</title><p id="Par3">AD patients had a significantly lower ALPS-Index vs. healthy controls (ActiGliA: AD: mean = 1.22, SD = 0.12; Controls: mean = 1.36, SD = 0.14, <italic toggle="yes">p</italic> = 0.004; DELCODE: AD: mean = 1.26, SD = 0.18; Controls: mean = 1.34, SD = 0.2, <italic toggle="yes">p</italic> = 0.035; ADNI: AD: mean = 1.08, SD = 0.24; Controls: mean = 1.19, SD = 0.13, <italic toggle="yes">p</italic> = 0.008). The ALPS-Index was associated with CSF Aβ concentration, WMH number and MMSE and CDR. WMH, found in the ROIs correlated negatively with the ALPS-Index.</p></sec><sec><title>Conclusions</title><p id="Par4">This study highlights the potential of the DTI-ALPS-Index as a biomarker for glymphatic dysfunction in AD. It underscores the importance of considering vascular factors and the glymphatic system in the pathogenesis and diagnosis of AD as WMHs in the ROI could cause disturbances and inaccurate indices.</p></sec><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1186/s13195-025-01707-9.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Perivascular space</kwd><kwd>Diffusion tensor imaging</kwd><kwd>Amyloid-beta</kwd><kwd>Cognitive decline</kwd><kwd>Alzheimer's disease</kwd><kwd>Dementia</kwd></kwd-group><funding-group><award-group><funding-source><institution>Klinikum der Universität München (6933)</institution></funding-source></award-group><open-access><p>Open Access funding enabled and organized by Projekt DEAL.</p></open-access></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>© BioMed Central Ltd., part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par5">Alzheimer’s disease (AD) is a chronic neurodegenerative disease, characterized by the progressive deterioration of neural circuits leading to cognitive decline and dementia. While extensive research on the neuropathological hallmarks of AD, such as amyloid-β (Aβ) plaques, neurofibrillary tangles, and glial responses has been carried out, the importance of vascular contributions has long been recognized but sometimes overlooked in earlier studies [<xref ref-type="bibr" rid="CR1">1</xref>]. According to the amyloid hypothesis, an imbalance between the production and clearance of Aβ results in the accumulation and aggregation within the brain and triggers a cascade of pathophysiological events with the formation of neurofibrillary tau tangles, loss of neurons and synaptic dysfunction ultimately resulting in dementia [<xref ref-type="bibr" rid="CR2">2</xref>]. The production of Aβ has received much attention as a therapeutic target against AD in recent years; less emphasis was placed on the modification of mechanisms related to Aβ clearance. It has been postulated that insufficient cerebral clearance of Aβ peptides which are produced at a normal rate account for most cases of sporadic AD [<xref ref-type="bibr" rid="CR3">3</xref>]. Until recently, transport across the blood-brain barrier (BBB) was considered as the main mechanism to remove Aβ from the brain; however, newer findings support the existence of additional important mechanisms [<xref ref-type="bibr" rid="CR4">4</xref>]. Bulk-flow of interstitial fluid (ISF) mediated by astroglia and the recently discovered glymphatic vessels in the meninges probably also make a meaningful contribution to Aβ clearance [<xref ref-type="bibr" rid="CR5">5</xref>]. Previously, it was thought that about 75% of Aβ is cleared by BBB transport and only 10% by the glymphatic system. However, recent photon imaging studies in mice, using microscopy with fluorescent tracers, have suggested that the glymphatic system contributes to a larger part of Aβ clearance than previously thought [<xref ref-type="bibr" rid="CR6">6</xref>]. The glymphatic system comprises the transport of cerebrospinal fluid (CSF) after para-arterial influx and transport via aquaporin 4 channels into the interstitium, followed by convective intestinal transport to efflux via the perivenous space into the lymphatic system [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>]. This system regulated by astrocytes is assumed to play a major role in the drainage of brain metabolites, and its malfunction may lead to the accumulation of waste products and is related to AD pathogenesis [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR9">9</xref>]. The glymphatic pathway has been visualized in rodents using a variety of imaging approaches; clinical imaging of the glymphatic pathway is an emerging field, and several innovative methods in humans intrathecal contrast agent injection has been used to visualize the glymphatic system [<xref ref-type="bibr" rid="CR10">10</xref>], a rather invasive imaging approach. Recently a novel technique “diffusion tensor image analysis along the perivascular space (DTI-ALPS; ALPS_Index) using non-invasive MR diffusion tensor imaging (DTI) based technique has been developed to evaluate the glymphatic system in vivo [<xref ref-type="bibr" rid="CR11">11</xref>]. Numerous studies have shown glymphatic insufficiency in a variety of diseases using this approach, which measures the ratio of water diffusivity along the perivascular space [<xref ref-type="bibr" rid="CR12">12</xref>–<xref ref-type="bibr" rid="CR14">14</xref>]. In AD and older adults at risk for dementia a decreased ALPS-Index compared to healthy controls was reported in two previous studies [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR15">15</xref>].</p><p id="Par6">Besides the dysfunction of the glymphatic system there is increasing evidence suggesting that cerebrovascular disease (CVD) and AD not only share common risk factors, but also have additive harmful effects on cognitive function [<xref ref-type="bibr" rid="CR16">16</xref>]. Studies have demonstrated that reducing cardiovascular risk protects against AD [<xref ref-type="bibr" rid="CR17">17</xref>]. A two-hits-mechanism where BBB disruption as a “first hit” is followed by Aβ accumulation as a “second hit” ultimately leading to full-blown AD has been proposed [<xref ref-type="bibr" rid="CR18">18</xref>]. A vast number of studies demonstrated links between established AD biomarkers and vascular abnormalities in AD. It has been shown that Aβ [<xref ref-type="bibr" rid="CR19">19</xref>], tau [<xref ref-type="bibr" rid="CR20">20</xref>] and glucose metabolism [<xref ref-type="bibr" rid="CR21">21</xref>] in AD are associated with microvascular damage, and it was suggested that vascular changes are among the earlies events in the course of the disease [<xref ref-type="bibr" rid="CR22">22</xref>]. A frequent finding in AD are white matter hyperintensities (WMH) observable on T2-weighted Fluid-attenuated inversion recovery (FLAIR) brain MRI scans. The pathophysiological origin of WMH has not yet been fully understood. Associations with cerebrovascular damage, microglial and endothelial cell activation and glial reorganization have been reported frequently, suggesting that WMH is a proxy measure of white matter damage [<xref ref-type="bibr" rid="CR23">23</xref>]. Recent studies have also reported associations between white matter changes and both Aβ [<xref ref-type="bibr" rid="CR24">24</xref>] and tau pathology [<xref ref-type="bibr" rid="CR25">25</xref>]. Additionally, the extent of WMH is correlated with cognitive impairment and an increased risk of dementia [<xref ref-type="bibr" rid="CR26">26</xref>].</p><p id="Par7">In our study, we first examined alterations in the glymphatic system integrity and function, specifically focusing on changes detected using the DTI-ALPS method, across three independent cohorts of individuals with AD compared to healthy controls. Additionally, we investigated the potential contamination of DTI-ALPS measurements by the concurrent presence of WMH in the regions analyzed, often ignored by previous analyses. Previous studies have demonstrated a correlation between the ALPS-Index and both the Mini-Mental State Examination (MMSE) scores, and Aβ as measured in PET imaging [<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR28">28</xref>]. However, to our knowledge, this is the first investigation that explicitly examines how impairments in the glymphatic system is associated with CSF Aβ levels. Furthermore, we assess the associations between glymphatic system impairments and cerebral small vessel disease, evidenced by WMH in FLAIR MRI.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Participants</title><p id="Par8">We tested our hypothesis in tree independent cohorts. Participants in all three cohorts were stratified by the following scheme: Alzheimer’s Disease (AD) patients, were defined as participants with a clinical dementia rating (CDR) &gt; = 0.5 [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR30">30</xref>] and positive Aβ42/40 status, determined by CSF. Healthy controls (HC) were defined as CDR = 0 and Aβ negative for CSF. For the cohort-specific CSF cutoff values, please see the CSF biomarker section. Data from three independent cohorts were analyzed equally to investigate the relationship between glymphatic system function and Alzheimer’s disease. The Activity of Cerebral Networks, Amyloid and Microglia in Aging (ActiGliA) study, a prospective, observational, single-center study of the Munich Cluster for Systems Neurology (SyNergy) at Ludwig-Maximilians-University (LMU) Munich, included <italic toggle="yes">n</italic> = 16 AD patients and <italic toggle="yes">n</italic> = 18 HC [<xref ref-type="bibr" rid="CR31">31</xref>], as seen in Fig. <xref rid="Fig1" ref-type="fig">1</xref>. The German Center for Neurodegenerative Diseases Longitudinal Cognitive Impairment and Dementia (DELCODE) [<xref ref-type="bibr" rid="CR32">32</xref>] study contributed <italic toggle="yes">n</italic> = 54 AD patients and <italic toggle="yes">n</italic> = 67 HC subjects (see Fig. <xref rid="Fig2" ref-type="fig">2</xref>), while the Alzheimer’s Disease Neuroimaging Initiative (ADNI) provided data from <italic toggle="yes">n</italic> = 43 AD patients and <italic toggle="yes">n</italic> = 49 HC, see Fig. <xref rid="Fig3" ref-type="fig">3</xref>. Participants from all three cohorts underwent DTI and FLAIR imaging for analysis. Each study was approved by the local ethics committee of the participating centers, including the ethics committee of LMU Munich (project numbers 17–755 and 17–569). Patients with early AD (subjective cognitive impairment, MCI and mild AD dementia) and age-matched cognitively normal controls were included after providing written informed consent in line with the declaration of Helsinki.</p><p id="Par9">
<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>Flowchart of ActiGliA Participant Inclusion and Exclusion Criteria. AD: Aβ+, CDR+; HC: Aβ-,CDR-</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e874" position="float" orientation="portrait" xlink:href="13195_2025_1707_Fig1_HTML.jpg"/></fig>
</p><p id="Par10">
<fig id="Fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>Flowchart of DELCODE Participant Inclusion and Exclusion Criteria. AD: Aβ+, CDR+; HC: Aβ-,CDR-</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e884" position="float" orientation="portrait" xlink:href="13195_2025_1707_Fig2_HTML.jpg"/></fig>
</p><p id="Par11">
<fig id="Fig3" position="float" orientation="portrait"><label>Fig. 3</label><caption><p>Flowchart of ADNI Participant Inclusion and Exclusion Criteria. AD: Aβ+, CDR+; HC: Aβ-,CDR-</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e894" position="float" orientation="portrait" xlink:href="13195_2025_1707_Fig3_HTML.jpg"/></fig>
</p></sec><sec id="Sec4"><title>CSF biomarkers analysis</title><p id="Par12">CSF biomarkers were evaluated using established commercially available assay kits, in all three cohorts, using aliquoted samples and a single lot of each reagent for each of the measured biomarkers. The electrochemiluminescence immunoassay (ECLIA) Elecsys cobas e 601 instrument (Roche Diagnostics GmbH, Penzberg, Germany) was used to quantify the CSF concentrations of Aβ42, p-tau181 in the ADNI cohort. CSF peptide measures in the DELCODE and ActiGliA cohort were performed using aliquoted samples using commercially available (Fujirebio, Malvern, PA) enzyme-linked immunosorbent assays (ELISAs). The following cutoffs for CSF Aβ42/40 were applied to determine whether a study participant was amyloid positive: Aβ42/40: &lt;= 0.08 [<xref ref-type="bibr" rid="CR33">33</xref>] for DELCODE and Aβ42/40: &lt;= 0.05 (ADNI and ActiGliA respectively) [<xref ref-type="bibr" rid="CR34">34</xref>].</p></sec><sec id="Sec5"><title>Clinical and cognitive testing</title><p id="Par13">To evaluate cognitive performance the MMSE was performed [<xref ref-type="bibr" rid="CR35">35</xref>]. Analysis details are presented in the supplemental material. Clinical dementia severity was determined using the Clinical Dementia Rating (CDR) global score [<xref ref-type="bibr" rid="CR30">30</xref>].</p></sec><sec id="Sec6"><title>MRI acquisition</title><p id="Par14">ActiGliA: MRI data for the entire ActiGliA cohort was acquired at the Department of Radiology of LMU Munich on a Siemens 3T Magnetom Skyra MR system (Siemens Healthineers, Erlangen, Germany). A 0.8 mm isovoxel high resolution T1-weighted structural MRI sequence (repetition time (TR), 2060 ms; echo time (TE), 2.17 ms; flip angle (FA), 12°; field of view (FoV), 240 mm) and a diffusion weighted imaging (DWI) MRI sequence with a multi-band acceleration factor 3 (TR, 3800 ms; TE, 104.8 ms; b-value, 2000 s/mm²; 108 diffusion directions; FA, 90°; FoV, 240 mm) were acquired. Matrix size: 120 × 120 with a voxel size of 2.0 × 2.0 × 2.0 mm and a FoV of 240 × 240 mm.</p><p id="Par15">DELCODE: DWI data were acquired with single-shot echo-planar imaging (EPI) on 3-Tesla MRI scanners (i.e., Siemens MAGNETOM TrioTim, Verio, Skyra, and Prisma; Siemens Healthcare, Erlangen, Germany). Acquisition parameters were the same across all scanners: GRAPPA acceleration factor 2; TR = 12,100 ms; TE = 88.0 ms; b-values = 700 and 1000 s/mm2 (30 directions each); 70 diffusion directions including 10 b = 0 images; FA, 90°; FoV, 240 × 240 × 144 mm3; phase encoding = anterior-to-posterior; matrix size = 120 × 120; voxel size, 2.0 mm isotropic; 72 axial slices; total acquisition time = 14 min 45 s. For the 3D FLAIR sequence, the acquisition parameters were as follows: TR = 5 s, TE = 394 ms, inversion time (TI) = 1.8 s, resolution = 1 × 1 × 1 mm3, matrix size = 256 × 256, 192 slices [<xref ref-type="bibr" rid="CR36">36</xref>].</p><p id="Par16">ADNI: The ADNI MRI acquisition protocol is reported elsewhere (JG_ADNI3_AAIC_poster_FINAL.pptx (usc.edu). In short, diffusion data were acquired using DWI, on 3-Tesla MRI scanners, following ADNI-3 Basic Protocol, with a geometry of FoV at reconstructed resolution in mm: 232 × 232 × 160; phase encoding = posterior-to-anterior; voxel size, 2 × 2 × 2 mm3; 80 axial slices. Following timing parameters in ms: TE = 56, TR = 7200, and a run time of 7:30 min. Single b-value = 1000 s/mm2, shell b = 0 images interleaved throughout if possible in product sequence. 3D FLAIR was acquired with a geometry of FoV at reconstructed resolution in mm: 256 × 256 × 160, voxel size, 1 × 1 × 1.2 mm3. Timing parameters in ms: TE = 119, TR = 4800, TI = 1650. With an approximate run time in minutes: 5:30. TE definition varies by vendor, effective TE is quoted.</p></sec><sec id="Sec7"><title>Preprocessing of the diffusion-weighted imaging and calculation of the ALPS-Index</title><p id="Par17">The ALPS-Index was estimated as previously described [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR36">36</xref>]. In short, we preprocessed the images by generating diffusivity maps from DTI data in the direction of the x-axis (right-left), y-axis (anterior-posterior), z-axis (inferior-superior), and color-coded fractional anisotropy (FA) maps of each subject. These images were used for the calculation of the ALPS-Index. Four regions-of-Interest (ROIs) with a radius of five-millimeter were then drawn manually in the centrum semiovale along the projection and association fibers orthogonal to the perivascular spaces at the level of the medullary veins on each side of the lateral ventricle on the color-coded FA map. Diffusivity was calculated in the direction of the x-axis, y-axis, and z-axis of the ROIs along the projection fibers and the association fibers as X-proj, Y-proj, Z-proj, X-assoc, Y-assoc, Z-assoc, respectively. The ratio between the mean measures of diffusion (ALPS-Index) were calculated as<disp-formula id="Equa"><alternatives><tex-math id="M1">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\:DTIALPS\_index=\frac{({meanX}_{proj}+{meanX}_{asoc})}{({meanY}_{proj}+mean{Z}_{assoc})}$$\end{document}</tex-math><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" orientation="portrait" xlink:href="13195_2025_1707_Article_Equa.gif"/></alternatives></disp-formula></p><p id="Par18">We calculated the ALPS-Index on the right and left side separately (ALPS-Index_R/ALPS-Index_L). Diffusivity along the X-axis in these areas have been proposed to represent the perivascular spaces’ diffusivity [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR36">36</xref>].</p></sec><sec id="Sec8"><title>Estimation of white matter lesions</title><p id="Par19">We assessed WMH using MRI FLAIR images. The lesions were segmented using the lesion prediction algorithm [<xref ref-type="bibr" rid="CR37">37</xref>] implemented in the LST toolbox version<italic toggle="yes">3.0.0</italic> (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.statistical-modelling.de/lst.html">www.statistical-modelling.de/lst.html</ext-link>) for SPM12. Parameters of this model fit were used to segment lesions by providing an estimate for the lesion probability for each voxel [<xref ref-type="bibr" rid="CR38">38</xref>].</p><p id="Par20">To enhance the robustness of our analysis, we developed a computational script to quantify the presence of WMHs within our defined ROI. In short, this script automates the quantification of WMH in specified ROIs by transforming hand-drawn DTI coordinates into FLAIR space, creating 5 mm spherical masks around these coordinates, and counting the intersecting WMH voxels. It efficiently processes multiple cases, facilitating the analysis of WMH load in defined brain regions. To and mitigate confounding of the ALPS-Index by WMHs, we decided to exclude participants exhibiting any level of WMH in our ROI (<italic toggle="yes">n</italic> = 48) from analyses investigating correlations and associations between the ALPS-Index and biomarkers, WMH volume in the rest of the brain (outside of the ROI), and clinical markers. However, these excluded participants were analyzed separately to evaluate the specific impact of WMH within the ROI on the ALPS-Index. This decision was informed by the observed negative correlations between WMH and ALPS-Index in ADNI and DELCODE, both cohorts with the most WMH detected, which could potentially obscure the interpretation of our findings. For a better understanding of how the images were processed, see Fig. <xref rid="Fig4" ref-type="fig">4</xref>. Specifically, we excluded <italic toggle="yes">n</italic> = 36 subjects, including AD and HC, from the ADNI, <italic toggle="yes">n</italic> = 10 from the DELCODE, and <italic toggle="yes">n</italic> = 2 participants from the ActiGliA dataset (see Tables <xref rid="Tab1" ref-type="table">1</xref> and <xref rid="Tab2" ref-type="table">2</xref> in RESULTS). The rationale for this exclusion criterion is grounded in the premise that vascular anomalies could erroneously affect the interpretation of ALPS-Index measurements, thereby skewing the assessment of glymphatic function.</p><p id="Par21">
<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table 1</label><caption><p>Correlation between ALPS indices and amyloid beta42/40 ratio</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="3" colspan="1"/><th align="left" colspan="4" rowspan="1">ActiGlia</th><th align="left" colspan="4" rowspan="1">ADNI</th><th align="left" colspan="4" rowspan="1">DELCODE</th></tr><tr><th align="left" colspan="4" rowspan="1">Aβ42/40</th><th align="left" colspan="4" rowspan="1">Aβ42/40</th><th align="left" colspan="4" rowspan="1">Aβ42/40</th></tr><tr><th align="left" colspan="1" rowspan="1">β</th><th align="left" colspan="1" rowspan="1">SE</th><th align="left" colspan="1" rowspan="1">Adj-<italic toggle="yes">R</italic>²</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">p</italic>-value</th><th align="left" colspan="1" rowspan="1">β</th><th align="left" colspan="1" rowspan="1">SE</th><th align="left" colspan="1" rowspan="1">Adj-<italic toggle="yes">R</italic>²</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">p</italic>-value</th><th align="left" colspan="1" rowspan="1">β</th><th align="left" colspan="1" rowspan="1">SE</th><th align="left" colspan="1" rowspan="1">Adj-<italic toggle="yes">R</italic>²</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">p</italic>-value</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">ALPS_comb</td><td char="." align="char" colspan="1" rowspan="1">-0.14</td><td char="." align="char" colspan="1" rowspan="1">0.34</td><td char="." align="char" colspan="1" rowspan="1">0.31</td><td char="." align="char" colspan="1" rowspan="1">0.675</td><td char="." align="char" colspan="1" rowspan="1">-0.17</td><td char="." align="char" colspan="1" rowspan="1">0.40</td><td char="." align="char" colspan="1" rowspan="1">0.05</td><td char="." align="char" colspan="1" rowspan="1">0.670</td><td char="." align="char" colspan="1" rowspan="1">-0.65</td><td char="." align="char" colspan="1" rowspan="1">0.24</td><td char="." align="char" colspan="1" rowspan="1">0.15</td><td char="." align="char" colspan="1" rowspan="1">0.009*</td></tr><tr><td align="left" colspan="1" rowspan="1">ALPS_R</td><td char="." align="char" colspan="1" rowspan="1">-0.08</td><td char="." align="char" colspan="1" rowspan="1">0.31</td><td char="." align="char" colspan="1" rowspan="1">0.39</td><td char="." align="char" colspan="1" rowspan="1">0.796</td><td char="." align="char" colspan="1" rowspan="1">-0.06</td><td char="." align="char" colspan="1" rowspan="1">0.35</td><td char="." align="char" colspan="1" rowspan="1">0.25</td><td char="." align="char" colspan="1" rowspan="1">0.877</td><td char="." align="char" colspan="1" rowspan="1">-0.58</td><td char="." align="char" colspan="1" rowspan="1">0.25</td><td char="." align="char" colspan="1" rowspan="1">0.11</td><td char="." align="char" colspan="1" rowspan="1">0.020*</td></tr><tr><td align="left" colspan="1" rowspan="1">ALPS_L</td><td char="." align="char" colspan="1" rowspan="1">-0.18</td><td char="." align="char" colspan="1" rowspan="1">0.35</td><td char="." align="char" colspan="1" rowspan="1">0.23</td><td char="." align="char" colspan="1" rowspan="1">0.621</td><td char="." align="char" colspan="1" rowspan="1">-0.06</td><td char="." align="char" colspan="1" rowspan="1">0.40</td><td char="." align="char" colspan="1" rowspan="1">0.06</td><td char="." align="char" colspan="1" rowspan="1">0.891</td><td char="." align="char" colspan="1" rowspan="1">-0.56</td><td char="." align="char" colspan="1" rowspan="1">0.24</td><td char="." align="char" colspan="1" rowspan="1">0.13</td><td char="." align="char" colspan="1" rowspan="1">0.022*</td></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">Abbreviations</italic>: ALPS_R, ALPS_L: calculated ALPS index on right R and left L hemisphere of the brain. ALPS_comb: combined ALPS index, by calculating the mean of Index for right and left hemishphere; adj-R²: adjusted R²; SE: Standard error; * significant difference with <italic toggle="yes">P</italic> &lt; 0.05. Calculated with multivariate linear regression analyses, using age, sex, years of education and diagnose (ADvsHC) as confounding variables</p></table-wrap-foot></table-wrap>
</p><p id="Par22">
<table-wrap id="Tab2" position="float" orientation="portrait"><label>Table 2</label><caption><p>Correlation between ALPS indices and amyloid beta42/40 ratio in AD group</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="3" colspan="1"/><th align="left" colspan="4" rowspan="1">ActiGlia</th><th align="left" colspan="4" rowspan="1">ADNI</th><th align="left" colspan="4" rowspan="1">DELCODE</th></tr><tr><th align="left" colspan="4" rowspan="1">Aβ42/40</th><th align="left" colspan="4" rowspan="1">Aβ42/40</th><th align="left" colspan="4" rowspan="1">Aβ42/40</th></tr><tr><th align="left" colspan="1" rowspan="1">β</th><th align="left" colspan="1" rowspan="1">SE</th><th align="left" colspan="1" rowspan="1">Adj-<italic toggle="yes">R</italic>²</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">p</italic>-value</th><th align="left" colspan="1" rowspan="1">β</th><th align="left" colspan="1" rowspan="1">SE</th><th align="left" colspan="1" rowspan="1">Adj-<italic toggle="yes">R</italic>²</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">p</italic>-value</th><th align="left" colspan="1" rowspan="1">β</th><th align="left" colspan="1" rowspan="1">SE</th><th align="left" colspan="1" rowspan="1">Adj-<italic toggle="yes">R</italic>²</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">p</italic>-value</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">ALPS_comb</td><td char="." align="char" colspan="1" rowspan="1">-0.33</td><td char="." align="char" colspan="1" rowspan="1">0.03</td><td char="." align="char" colspan="1" rowspan="1">0.48</td><td char="." align="char" colspan="1" rowspan="1">0.138</td><td char="." align="char" colspan="1" rowspan="1">-0.26</td><td char="." align="char" colspan="1" rowspan="1">8.50</td><td char="." align="char" colspan="1" rowspan="1">-0.08</td><td char="." align="char" colspan="1" rowspan="1">0.255</td><td char="." align="char" colspan="1" rowspan="1">-0.40</td><td char="." align="char" colspan="1" rowspan="1">2.30</td><td char="." align="char" colspan="1" rowspan="1">0.23</td><td char="." align="char" colspan="1" rowspan="1">0.003*</td></tr><tr><td align="left" colspan="1" rowspan="1">ALPS_R</td><td char="." align="char" colspan="1" rowspan="1">-0.18</td><td char="." align="char" colspan="1" rowspan="1">0.04</td><td char="." align="char" colspan="1" rowspan="1">0.57</td><td char="." align="char" colspan="1" rowspan="1">0.345</td><td char="." align="char" colspan="1" rowspan="1">-0.30</td><td char="." align="char" colspan="1" rowspan="1">5.22</td><td char="." align="char" colspan="1" rowspan="1">0.07</td><td char="." align="char" colspan="1" rowspan="1">0.167</td><td char="." align="char" colspan="1" rowspan="1">-0.45</td><td char="." align="char" colspan="1" rowspan="1">2.50</td><td char="." align="char" colspan="1" rowspan="1">0.32</td><td char="." align="char" colspan="1" rowspan="1">0.000*</td></tr><tr><td align="left" colspan="1" rowspan="1">ALPS_L</td><td char="." align="char" colspan="1" rowspan="1">-0.45</td><td char="." align="char" colspan="1" rowspan="1">0.03</td><td char="." align="char" colspan="1" rowspan="1">0.10</td><td char="." align="char" colspan="1" rowspan="1">0.125</td><td char="." align="char" colspan="1" rowspan="1">-0.13</td><td char="." align="char" colspan="1" rowspan="1">5.43</td><td char="." align="char" colspan="1" rowspan="1">-0.06</td><td char="." align="char" colspan="1" rowspan="1">0.575</td><td char="." align="char" colspan="1" rowspan="1">-0.26</td><td char="." align="char" colspan="1" rowspan="1">2.60</td><td char="." align="char" colspan="1" rowspan="1">0.08</td><td char="." align="char" colspan="1" rowspan="1">0.062</td></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">Abbreviations</italic>: ALPS_R, ALPS_L: calculated ALPS index on right R and left L hemisphere of the brain. ALPS_comb: combined ALPS index, by calculating the mean of Index for right and left hemishphere; adj-R²: adjusted R²; SE: Standard error; * significant difference with <italic toggle="yes">P</italic> &lt; 0.05. Calculated with multivariate linear regression analyses, using age, sex, and years of education as confounding variables</p></table-wrap-foot></table-wrap>
</p><p id="Par23">
<fig id="Fig4" position="float" orientation="portrait"><label>Fig. 4</label><caption><p>Schematic illustration of the analysis process and data from representative participants. (<bold>A</bold>) Analysis process from initial diffusion weighted imaging (DWI) images to calculate ALPS indices. (<bold>B</bold>) Analysis process to calculate volume of white-matter hyperintensities (WMH) in regions of interest (ROI) and data from 2 representative subjects from ADNI cohort, which illustrates how higher WMH-Volume in ROI might interfere with ALPS-Index in healthy controls. ALPS: diffusion tensor image analysis along the perivascular space</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e1364" position="float" orientation="portrait" xlink:href="13195_2025_1707_Fig4_HTML.jpg"/></fig>
</p></sec><sec id="Sec9"><title>Statistical analysis</title><p id="Par24">Group differences were analyzed using an analysis of covariance (ANCOVA) adjusted for age and sex. Statistical analysis was performed using Python 3, including the libraries NumPy, Pandas, and Matplotlib. Associations between ALPS-Index and Aβ, WMH, CDR and MMSE were analyzed using multiple linear regression models in SPSS version 27 using age, sex and years of education and diagnose (AD vs. HC) as confounding variables. Statistical significance was considered at an alpha level = 0.05. To address the non-normal distribution of WMH volume data, we applied a log-transformation before conducting t-tests or multiple linear regression analyses.</p></sec></sec><sec id="Sec10"><title>Results</title><p id="Par25">The sociodemographic and clinical characteristics of the three cohorts (ActiGliA, DELCODE, ADNI) are presented in Supplementary Tables <xref rid="MOESM1" ref-type="media">1</xref>, <xref rid="MOESM1" ref-type="media">2</xref> and <xref rid="MOESM1" ref-type="media">3</xref>. The ALPS-Index is higher in HC, compared to AD in all three cohorts respectively (Table <xref rid="Tab3" ref-type="table">3</xref>; Fig. <xref rid="Fig5" ref-type="fig">5</xref>). There was no difference in detected number nor volume of WMH between AD and HC in most cohorts, besides WMH count in DELCODE, with a higher number of WMH in AD, compared to HC (p-value = 0.001).</p><p id="Par26">
<table-wrap id="Tab3" position="float" orientation="portrait"><label>Table 3</label><caption><p>Group differences between AD (Alzheimers diesease dementia patients) and HC (healthy controls) in the DTI_ALPS-Index</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Cohort</th><th align="left" colspan="1" rowspan="1">Location</th><th align="left" colspan="1" rowspan="1">AD (mean ± SD)</th><th align="left" colspan="1" rowspan="1">HC (mean ± SD)</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">P</italic>-Value</th><th align="left" colspan="1" rowspan="1">Cohens d</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">ADNI</td><td align="left" colspan="1" rowspan="1">ALPS_comb</td><td char="±" align="char" colspan="1" rowspan="1">1.080 ± 0.236</td><td char="±" align="char" colspan="1" rowspan="1">1.190 <bold>±</bold> 0.132</td><td char="." align="char" colspan="1" rowspan="1">0.008*</td><td char="." align="char" colspan="1" rowspan="1">-0.575</td></tr><tr><td align="left" colspan="1" rowspan="1">ADNI</td><td align="left" colspan="1" rowspan="1">ALPS_R</td><td char="±" align="char" colspan="1" rowspan="1">1.088 ± 0.173</td><td char="±" align="char" colspan="1" rowspan="1">1.207 <bold>±</bold> 0.154</td><td char="." align="char" colspan="1" rowspan="1">0.001*</td><td char="." align="char" colspan="1" rowspan="1">-0.727</td></tr><tr><td align="left" colspan="1" rowspan="1">ADNI</td><td align="left" colspan="1" rowspan="1">ALPS_L</td><td char="±" align="char" colspan="1" rowspan="1">1.123 ± 0.186</td><td char="±" align="char" colspan="1" rowspan="1">1.174 <bold>±</bold> 0.147</td><td char="." align="char" colspan="1" rowspan="1">0.149</td><td char="." align="char" colspan="1" rowspan="1">-0.304</td></tr><tr><td align="left" colspan="1" rowspan="1">DELCODE</td><td align="left" colspan="1" rowspan="1">ALPS_comb</td><td char="±" align="char" colspan="1" rowspan="1">1.262 ± 0.180</td><td char="±" align="char" colspan="1" rowspan="1">1.336 <bold>±</bold> 0.197</td><td char="." align="char" colspan="1" rowspan="1">0.035*</td><td char="." align="char" colspan="1" rowspan="1">-0.392</td></tr><tr><td align="left" colspan="1" rowspan="1">DELCODE</td><td align="left" colspan="1" rowspan="1">ALPS_R</td><td char="±" align="char" colspan="1" rowspan="1">1.245 ± 0.208</td><td char="±" align="char" colspan="1" rowspan="1">1.332 <bold>±</bold> 0.254</td><td char="." align="char" colspan="1" rowspan="1">0.048*</td><td char="." align="char" colspan="1" rowspan="1">-0.375</td></tr><tr><td align="left" colspan="1" rowspan="1">DELCODE</td><td align="left" colspan="1" rowspan="1">ALPS_L</td><td char="±" align="char" colspan="1" rowspan="1">1.278 ± 0.185</td><td char="±" align="char" colspan="1" rowspan="1">1.341 <bold>±</bold> 0.199</td><td char="." align="char" colspan="1" rowspan="1">0.081</td><td char="." align="char" colspan="1" rowspan="1">-0.328</td></tr><tr><td align="left" colspan="1" rowspan="1">ActiGliA</td><td align="left" colspan="1" rowspan="1">ALPS_comb</td><td char="±" align="char" colspan="1" rowspan="1">1.217 ± 0.122</td><td char="±" align="char" colspan="1" rowspan="1">1.356 <bold>±</bold> 0.139</td><td char="." align="char" colspan="1" rowspan="1">0.004*</td><td char="." align="char" colspan="1" rowspan="1">-1.063</td></tr><tr><td align="left" colspan="1" rowspan="1">ActiGliA</td><td align="left" colspan="1" rowspan="1">ALPS_R</td><td char="±" align="char" colspan="1" rowspan="1">1.217 ± 0.183</td><td char="±" align="char" colspan="1" rowspan="1">1.336 <bold>±</bold> 0.165</td><td char="." align="char" colspan="1" rowspan="1">0.055</td><td char="." align="char" colspan="1" rowspan="1">-0.683</td></tr><tr><td align="left" colspan="1" rowspan="1">ActiGliA</td><td align="left" colspan="1" rowspan="1">ALPS_L</td><td char="±" align="char" colspan="1" rowspan="1">1.217 ± 0.104</td><td char="±" align="char" colspan="1" rowspan="1">1.377 <bold>±</bold> 0.152</td><td char="." align="char" colspan="1" rowspan="1">0.001*</td><td char="." align="char" colspan="1" rowspan="1">-1.229</td></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">Abbreviation</italic>: ALPS_R, ALPS_L: calculated ALPS-Index on right R and left L hemisphere of the brain. ALPS_comb: combined ALPS-Index, by calculating the mean of Index for right and left hemisphere. SD: Standard deviation.* significant difference with <italic toggle="yes">P</italic> &lt; 0.05. Participants with WMH contamination of the ALPS calculation were omitted from the analysis. Calculated using an ANOVA adjusted for age and sex</p></table-wrap-foot></table-wrap>
</p><sec id="Sec11"><title>ALPS-Index in Alzheimer’s disease</title><p id="Par27">In this analysis of the ALPS-Index, significant group differences between AD patients and HC are observed. In the ADNI cohort, the combined ALPS-Index (ALPS_comb) shows a significantly lower value in AD patients compared to HC (1.080 ± 0.236 vs. 1.190 ± 0.132, <italic toggle="yes">p</italic> = 0.008, Cohen’s d = -0.575). Similar findings are seen for the right hemisphere (ALPS_R) in the ADNI cohort (<italic toggle="yes">p</italic> = 0.001, Cohen’s d = -0.727).</p><p id="Par28">In the DELCODE cohort, significant differences are also noted in the combined ALPS-Index (<italic toggle="yes">p</italic> = 0.035, Cohen’s d = -0.392) and the right hemisphere (<italic toggle="yes">p</italic> = 0.048, Cohen’s d = -0.375). The ActiGliA cohort demonstrates the most pronounced effect sizes, with a combined ALPS-Index of 1.217 ± 0.122 in AD patients versus 1.356 ± 0.139 in HC (<italic toggle="yes">p</italic> = 0.004, Cohen’s d = -1.063), and a particularly strong difference in the left hemisphere (<italic toggle="yes">p</italic> = 0.001, Cohen’s d = -1.229). See Table <xref rid="Tab3" ref-type="table">3</xref>; Fig. <xref rid="Fig5" ref-type="fig">5</xref>.</p><p id="Par29">
<fig id="Fig5" position="float" orientation="portrait"><label>Fig. 5</label><caption><p>Boxplots in all 3 cohorts comparing ALPS-Indices combined, left side and right side amongst patients with Alzheimer’s dementia (AD) and healthy control participants (HC)</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e1622" position="float" orientation="portrait" xlink:href="13195_2025_1707_Fig5_HTML.jpg"/></fig>
</p></sec><sec id="Sec12"><title>Associations between ALPS-Index and AD biomarkers</title><p id="Par30">Subsequent multivariate linear regression analyses (adjusted for age, sex, years of education and diagnose (AD, HC)) revealed correlations between the ALPS indices and Aβ42 across all three cohorts (Tables <xref rid="Tab4" ref-type="table">4</xref> and <xref rid="Tab1" ref-type="table">1</xref>; Fig. <xref rid="Fig6" ref-type="fig">6</xref>). A significant association between Aβ ratio 42/40 and all ALPS indices was found in DELCODE (ALPS_comb: beta = -0.645; p-value = 0.009). For ActiGlia, Aβ42 showed a significant association with ALPS_L index (beta = 0.531; p-value = 0.010). For ADNI, no significant associations between ALPS indices and Aβ42 or Aβ42/40 were found (all p-values &gt; 0.071).</p><p id="Par31">
<table-wrap id="Tab4" position="float" orientation="portrait"><label>Table 4</label><caption><p>Correlation between ALPS indices and Amyloid-beta 42</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="3" colspan="1"/><th align="left" colspan="4" rowspan="1">ActiGlia</th><th align="left" colspan="4" rowspan="1">ADNI</th><th align="left" colspan="4" rowspan="1">DELCODE</th></tr><tr><th align="left" colspan="4" rowspan="1">Aβ42</th><th align="left" colspan="4" rowspan="1">Aβ42</th><th align="left" colspan="4" rowspan="1">Aβ42</th></tr><tr><th align="left" colspan="1" rowspan="1">β</th><th align="left" colspan="1" rowspan="1">SE</th><th align="left" colspan="1" rowspan="1">Adj-<italic toggle="yes">R</italic>²</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">p</italic>-value</th><th align="left" colspan="1" rowspan="1">β</th><th align="left" colspan="1" rowspan="1">SE</th><th align="left" colspan="1" rowspan="1">Adj-<italic toggle="yes">R</italic>²</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">p</italic>-value</th><th align="left" colspan="1" rowspan="1">β</th><th align="left" colspan="1" rowspan="1">SE</th><th align="left" colspan="1" rowspan="1">Adj-<italic toggle="yes">R</italic>²</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">p</italic>-value</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">ALPS_comb</td><td char="." align="char" colspan="1" rowspan="1">0.47</td><td char="." align="char" colspan="1" rowspan="1">0.19</td><td char="." align="char" colspan="1" rowspan="1">0.43</td><td char="." align="char" colspan="1" rowspan="1">0.019*</td><td char="." align="char" colspan="1" rowspan="1">0.25</td><td char="." align="char" colspan="1" rowspan="1">0.19</td><td char="." align="char" colspan="1" rowspan="1">0.04</td><td char="." align="char" colspan="1" rowspan="1">0.206</td><td char="." align="char" colspan="1" rowspan="1">0.25</td><td char="." align="char" colspan="1" rowspan="1">0.16</td><td char="." align="char" colspan="1" rowspan="1">0.11</td><td char="." align="char" colspan="1" rowspan="1">0.124</td></tr><tr><td align="left" colspan="1" rowspan="1">ALPS_R</td><td char="." align="char" colspan="1" rowspan="1">0.31</td><td char="." align="char" colspan="1" rowspan="1">0.18</td><td char="." align="char" colspan="1" rowspan="1">0.45</td><td char="." align="char" colspan="1" rowspan="1">0.104</td><td char="." align="char" colspan="1" rowspan="1">0.27</td><td char="." align="char" colspan="1" rowspan="1">0.17</td><td char="." align="char" colspan="1" rowspan="1">0.24</td><td char="." align="char" colspan="1" rowspan="1">0.133</td><td char="." align="char" colspan="1" rowspan="1">0.30</td><td char="." align="char" colspan="1" rowspan="1">0.16</td><td char="." align="char" colspan="1" rowspan="1">0.09</td><td char="." align="char" colspan="1" rowspan="1">0.071</td></tr><tr><td align="left" colspan="1" rowspan="1">ALPS_L</td><td char="." align="char" colspan="1" rowspan="1">0.53</td><td char="." align="char" colspan="1" rowspan="1">0.19</td><td char="." align="char" colspan="1" rowspan="1">0.39</td><td char="." align="char" colspan="1" rowspan="1">0.010*</td><td char="." align="char" colspan="1" rowspan="1">0.35</td><td char="." align="char" colspan="1" rowspan="1">0.19</td><td char="." align="char" colspan="1" rowspan="1">0.10</td><td char="." align="char" colspan="1" rowspan="1">0.072</td><td char="." align="char" colspan="1" rowspan="1">0.13</td><td char="." align="char" colspan="1" rowspan="1">0.16</td><td char="." align="char" colspan="1" rowspan="1">0.10</td><td char="." align="char" colspan="1" rowspan="1">0.416</td></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">Abbreviations</italic>: ALPS_R, ALPS_L: calculated ALPS index on right R and left L hemisphere of the brain. ALPS_comb: combined ALPS index, by calculating the mean of Index for right and left hemishphere; adj-R<sup>2</sup>: adjusted R<sup>2</sup>; SE: Standard error; * significant difference with <italic toggle="yes">P</italic> &lt; 0.05. Calculated with multivariate linear regression analyses, using age, sex years of education and diagnose (ADvsHC) as confounding variables</p></table-wrap-foot></table-wrap>
</p><p id="Par32">Additionally, we performed multivariate linear regression analyses specifically within the AD group to examine AD-specific correlations of the ALPS indices, beyond investigating group differences between HC and AD. These analyses, also adjusted for age, sex, and years of education, revealed slightly different results (see Tables <xref rid="Tab5" ref-type="table">5</xref> and <xref rid="Tab2" ref-type="table">2</xref>). Amyloid-beta 42 correlates significantly with the ALPS Index on the left side of the brain in ADNI (beta = 0.43; p-value = 0.042). Where we were able to detect significant correlation in the ActiGliA cohort and Aβ42 before, we were unable to see the same results in just the AD group with p-values &gt; = 0.249.</p><p id="Par33">
<table-wrap id="Tab5" position="float" orientation="portrait"><label>Table 5</label><caption><p>Correlation between ALPS indices and Amyloid-beta 42 in AD</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="3" colspan="1"/><th align="left" colspan="4" rowspan="1">ActiGlia</th><th align="left" colspan="4" rowspan="1">ADNI</th><th align="left" colspan="4" rowspan="1">DELCODE</th></tr><tr><th align="left" colspan="4" rowspan="1">Aβ42</th><th align="left" colspan="4" rowspan="1">Aβ42</th><th align="left" colspan="4" rowspan="1">Aβ42</th></tr><tr><th align="left" colspan="1" rowspan="1">β</th><th align="left" colspan="1" rowspan="1">SE</th><th align="left" colspan="1" rowspan="1">Adj-<italic toggle="yes">R</italic>²</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">p</italic>-value</th><th align="left" colspan="1" rowspan="1">β</th><th align="left" colspan="1" rowspan="1">SE</th><th align="left" colspan="1" rowspan="1">Adj-<italic toggle="yes">R</italic>²</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">p</italic>-value</th><th align="left" colspan="1" rowspan="1">β</th><th align="left" colspan="1" rowspan="1">SE</th><th align="left" colspan="1" rowspan="1">Adj-<italic toggle="yes">R</italic>²</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">p</italic>-value</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">ALPS_comb</td><td char="." align="char" colspan="1" rowspan="1">0.18</td><td char="." align="char" colspan="1" rowspan="1">0.00</td><td char="." align="char" colspan="1" rowspan="1">0.39</td><td char="." align="char" colspan="1" rowspan="1">0.471</td><td char="." align="char" colspan="1" rowspan="1">0.09</td><td char="." align="char" colspan="1" rowspan="1">0.00</td><td char="." align="char" colspan="1" rowspan="1">-0.14</td><td char="." align="char" colspan="1" rowspan="1">0.707</td><td char="." align="char" colspan="1" rowspan="1">-0.12</td><td char="." align="char" colspan="1" rowspan="1">0.00</td><td char="." align="char" colspan="1" rowspan="1">0.09</td><td char="." align="char" colspan="1" rowspan="1">0.437</td></tr><tr><td align="left" colspan="1" rowspan="1">ALPS_R</td><td char="." align="char" colspan="1" rowspan="1">0.24</td><td char="." align="char" colspan="1" rowspan="1">0.00</td><td char="." align="char" colspan="1" rowspan="1">0.60</td><td char="." align="char" colspan="1" rowspan="1">0.249</td><td char="." align="char" colspan="1" rowspan="1">-0.08</td><td char="." align="char" colspan="1" rowspan="1">0.00</td><td char="." align="char" colspan="1" rowspan="1">-0.01</td><td char="." align="char" colspan="1" rowspan="1">0.705</td><td char="." align="char" colspan="1" rowspan="1">-0.06</td><td char="." align="char" colspan="1" rowspan="1">0.00</td><td char="." align="char" colspan="1" rowspan="1">0.13</td><td char="." align="char" colspan="1" rowspan="1">0.679</td></tr><tr><td align="left" colspan="1" rowspan="1">ALPS_L</td><td char="." align="char" colspan="1" rowspan="1">0.00</td><td char="." align="char" colspan="1" rowspan="1">0.00</td><td char="." align="char" colspan="1" rowspan="1">-0.12</td><td char="." align="char" colspan="1" rowspan="1">0.997</td><td char="." align="char" colspan="1" rowspan="1">0.43</td><td char="." align="char" colspan="1" rowspan="1">0.00</td><td char="." align="char" colspan="1" rowspan="1">0.24</td><td char="." align="char" colspan="1" rowspan="1">0.042*</td><td char="." align="char" colspan="1" rowspan="1">-0.16</td><td char="." align="char" colspan="1" rowspan="1">0.00</td><td char="." align="char" colspan="1" rowspan="1">0.03</td><td char="." align="char" colspan="1" rowspan="1">0.306</td></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">Abbreviations</italic>: ALPS_R, ALPS_L: calculated ALPS index on right R and left L hemisphere of the brain. ALPS_comb: combined ALPS index, by calculating the mean of Index for right and left hemishphere; adj-R<sup>2</sup>: adjusted R<sup>2</sup>; SE: Standard error; * significant difference with <italic toggle="yes">P</italic> &lt; 0.05. Calculated with multivariate linear regression analyses, using age, sex, and years of education as confounding variables</p></table-wrap-foot></table-wrap>
</p><p id="Par34">Aβ40/42-ratio correlates significantly with the combined and right ALPS-Index in DELCODE (ALPS_comb: beta = 0.255; p-value = 0.003).</p><p id="Par35">
<fig id="Fig6" position="float" orientation="portrait"><label>Fig. 6</label><caption><p>Regression plots of all 3 cohorts, outliers removed, indicating correlation between ALPS_comb and Amyloid beta values</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e2021" position="float" orientation="portrait" xlink:href="13195_2025_1707_Fig6_HTML.jpg"/></fig>
</p></sec></sec><sec id="Sec13"><title>Associations between ALPS and WMH</title><sec id="Sec14"><title>Subsequent analyses focused on WMHs specifically located within the 5 mm ROIs, conducted with participants who were excluded from other calculations</title><p id="Par36">In the correlation analysis between ALPS indices and WMH volume, found specifically in the 5 mm-sphere ROI, the multivariate regression revealed significant associations in several cohorts. In the ADNI cohort, the right hemisphere ALPS-Index was negatively correlated with WMH volume (β = -0.217, <italic toggle="yes">p</italic> = 0.040), as was the left hemisphere ALPS-Index in the DELCODE cohort (β = -0.171, <italic toggle="yes">p</italic> = 0.049). No significant correlations were found in the ActiGlia cohort.</p><p id="Par37">When combining all three cohorts, a significant negative correlation was observed between WMH volume and ALPS_comb (β = 0.154, <italic toggle="yes">p</italic> = 0.010 for WMH_comb), with consistent findings for ALPS_R (β = -0.202, <italic toggle="yes">p</italic> = 0.001). See Tables <xref rid="Tab6" ref-type="table">6</xref> and <xref rid="Tab7" ref-type="table">7</xref>; Fig. <xref rid="Fig7" ref-type="fig">7</xref>.</p><p id="Par38">
<table-wrap id="Tab6" position="float" orientation="portrait"><label>Table 6</label><caption><p>Correlation between ALPS indices and WMH found in the 5 mm-sphere- ROI in the 3 cohorts</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="3" colspan="1"/><th align="left" colspan="6" rowspan="1">WMH Volume detected in ROI (left and right side combined)</th></tr><tr><th align="left" colspan="2" rowspan="1">ActiGlia (<italic toggle="yes">n</italic> = 2)</th><th align="left" colspan="2" rowspan="1">ADNI (<italic toggle="yes">n</italic> = 36)</th><th align="left" colspan="2" rowspan="1">DELCODE (<italic toggle="yes">n</italic> = 10)</th></tr><tr><th align="left" colspan="1" rowspan="1">β</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">p</italic>-value</th><th align="left" colspan="1" rowspan="1">β</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">p</italic>-value</th><th align="left" colspan="1" rowspan="1">β</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">p</italic>-value</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">ALPS_comb</td><td char="." align="char" colspan="1" rowspan="1">0.067</td><td char="." align="char" colspan="1" rowspan="1">0.675</td><td char="." align="char" colspan="1" rowspan="1">-0.103</td><td char="." align="char" colspan="1" rowspan="1">0.373</td><td char="." align="char" colspan="1" rowspan="1">-0.215</td><td char="." align="char" colspan="1" rowspan="1">0.014*</td></tr><tr><td align="left" colspan="1" rowspan="1">ALPS_R</td><td char="." align="char" colspan="1" rowspan="1">0.072</td><td char="." align="char" colspan="1" rowspan="1">0.625</td><td char="." align="char" colspan="1" rowspan="1">-0.217</td><td char="." align="char" colspan="1" rowspan="1">0.040*</td><td char="." align="char" colspan="1" rowspan="1">-0.208</td><td char="." align="char" colspan="1" rowspan="1">0.022*</td></tr><tr><td align="left" colspan="1" rowspan="1">ALPS_L</td><td char="." align="char" colspan="1" rowspan="1">0.047</td><td char="." align="char" colspan="1" rowspan="1">0.784</td><td char="." align="char" colspan="1" rowspan="1">-0.068</td><td char="." align="char" colspan="1" rowspan="1">0.562</td><td char="." align="char" colspan="1" rowspan="1">-0.171</td><td char="." align="char" colspan="1" rowspan="1">0.049*</td></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">Abbreviations</italic>: ALPS_R, ALPS_L: calculated ALPS-Index on right R and left L hemisphere of the brain. ALPS_comb: combined ALPS-Index, by calculating the mean of Index for right and left hemishphere. * significant difference with <italic toggle="yes">P</italic> &lt; 0.05. Calculated with multivariate linear regression analyses, using age, sex, diagnose and years of education as confounding variable</p></table-wrap-foot></table-wrap>
</p><p id="Par39">
<table-wrap id="Tab7" position="float" orientation="portrait"><label>Table 7</label><caption><p>Correlation between ALPS indices and WMH found in the 5 mm-sphere- ROI with the 3 cohorts combined (<italic toggle="yes">n</italic> = 48)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="13" rowspan="1">WMH Volume detected in ROI</th></tr><tr><th align="left" rowspan="2" colspan="1"/><th align="left" colspan="4" rowspan="1">WMH_comb</th><th align="left" colspan="4" rowspan="1">WMH_R</th><th align="left" colspan="4" rowspan="1">WMH_L</th></tr><tr><th align="left" colspan="1" rowspan="1">β</th><th align="left" colspan="1" rowspan="1">SE</th><th align="left" colspan="1" rowspan="1">Adj-R ²</th><th align="left" colspan="1" rowspan="1">p-value</th><th align="left" colspan="1" rowspan="1">β</th><th align="left" colspan="1" rowspan="1">SE</th><th align="left" colspan="1" rowspan="1">Adj-R ²</th><th align="left" colspan="1" rowspan="1">p-value</th><th align="left" colspan="1" rowspan="1">β</th><th align="left" colspan="1" rowspan="1">SE</th><th align="left" colspan="1" rowspan="1">Adj-R ²</th><th align="left" colspan="1" rowspan="1">p-value</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">ALPS_comb</td><td char="." align="char" colspan="1" rowspan="1">0.154</td><td align="left" colspan="1" rowspan="1">0.053</td><td align="left" colspan="1" rowspan="1">0.18</td><td align="left" colspan="1" rowspan="1">0.010*</td><td char="." align="char" colspan="1" rowspan="1">-0.142</td><td align="left" colspan="1" rowspan="1">0.084</td><td align="left" colspan="1" rowspan="1">0.18</td><td align="left" colspan="1" rowspan="1">0.018*</td><td char="." align="char" colspan="1" rowspan="1">-0.133</td><td align="left" colspan="1" rowspan="1">0.109</td><td align="left" colspan="1" rowspan="1">0.18</td><td align="left" colspan="1" rowspan="1">0.027*</td></tr><tr><td align="left" colspan="1" rowspan="1">ALPS_R</td><td char="." align="char" colspan="1" rowspan="1">-0.202</td><td align="left" colspan="1" rowspan="1">0.058</td><td align="left" colspan="1" rowspan="1">0.16</td><td align="left" colspan="1" rowspan="1">0.001*</td><td char="." align="char" colspan="1" rowspan="1">-0.202</td><td align="left" colspan="1" rowspan="1">0.093</td><td align="left" colspan="1" rowspan="1">0.16</td><td align="left" colspan="1" rowspan="1">0.001*</td><td char="." align="char" colspan="1" rowspan="1">-0.154</td><td align="left" colspan="1" rowspan="1">0.120</td><td align="left" colspan="1" rowspan="1">0.14</td><td align="left" colspan="1" rowspan="1">0.013*</td></tr><tr><td align="left" colspan="1" rowspan="1">ALPS_L</td><td char="." align="char" colspan="1" rowspan="1">-0.117</td><td align="left" colspan="1" rowspan="1">0.051</td><td align="left" colspan="1" rowspan="1">0.17</td><td align="left" colspan="1" rowspan="1">0.055*</td><td char="." align="char" colspan="1" rowspan="1">-0.095</td><td align="left" colspan="1" rowspan="1">0.081</td><td align="left" colspan="1" rowspan="1">0.16</td><td align="left" colspan="1" rowspan="1">0.120</td><td char="." align="char" colspan="1" rowspan="1">-0.118</td><td align="left" colspan="1" rowspan="1">0.104</td><td align="left" colspan="1" rowspan="1">0.17</td><td align="left" colspan="1" rowspan="1">0.052</td></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">Abbreviations: aR</italic> ²<italic toggle="yes">= adjusted R squared; SE: Standard Error;</italic> ALPS_R, ALPS_L: calculated ALPS-Index on right R and left L hemisphere of the brain. ALPS_comb: combined ALPS-Index, WMH_R, WMH_L: volume of WMH in 5 mm sphere ROI on right and left hemisphere, WMH_comb: left and right side combined. * significant difference with <italic toggle="yes">P</italic> &lt; 0.05. Calculated with multivariate linear regression analyses, using age, sex, diagnose and cohort as confounding variable</p></table-wrap-foot></table-wrap>
</p><p id="Par40">
<fig id="Fig7" position="float" orientation="portrait"><label>Fig. 7</label><caption><p>Regression plots of all 3 cohorts combined, showing volume of WMH in ROI - in the subjects excluded from the other calculations - and the different ALPS indices, indicating a negative correlation between ALPS-Index and WMH found in the specific region, where ALPS is calculated</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e2337" position="float" orientation="portrait" xlink:href="13195_2025_1707_Fig7_HTML.jpg"/></fig>
</p></sec><sec id="Sec15"><title>Analyses focused on WMHs located in the rest of the brain, outside the 5 mm ROI, conducted with the regular participant cohort</title><p id="Par41">Distinct patterns emerged concerning WMH. In particular, a significant correlation between WMH count and the ALPS index was observed in the DELCODE cohort (Analysis with AD and HC included, but diagnose as confounding variable: ALPS_comb: beta = -0.362; p-value = 0.002. Analysis in AD group, without HC: ALPS_comb: beta = -0.377; p-value = 0.013; ALPS_L: beta = -0.416; p-value = 0.008). In the ActiGliA cohort, the p-values were not statistically significant at the 0.05 level, but there was an indication of a relationship between WMH volume and the ALPS_R index (beta = -0.290; p-value = 0.077). However, no such relationship was evident in the ADNI cohort (Fig. <xref rid="Fig8" ref-type="fig">8</xref>).</p><p id="Par42">
<fig id="Fig8" position="float" orientation="portrait"><label>Fig. 8</label><caption><p>Regression plots of all 3 cohorts, outliers removed, indicating correlation between ALPS_comb and WMH findings</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e2354" position="float" orientation="portrait" xlink:href="13195_2025_1707_Fig8_HTML.jpg"/></fig>
</p></sec><sec id="Sec16"><title>ALPS-Index and its associations with clinical and cognitive markers</title><p id="Par43">In the ADNI and ActiGliA cohorts, associations were observed between the ALPS indices and cognitive assessment measures—specifically, the MMSE in ADNI (ALPS_comb: p-value: 0.038, beta:-0.307), CDR in ADNI (ALPS_L: p-value:0.035, beta:0.469) and the CDR in ActiGliA (ALPS_R: p-value:0.031, beta:-0.797) — suggesting a link with cognitive decline and disease progression. However, these correlations were not consistently replicated in the DELCODE cohort (p-value &gt; 0.168), as seen in Fig. <xref rid="Fig9" ref-type="fig">9</xref>. When comparing high vs. low CDR and MMSE, the Mann-Whitney U test results show that CDR (0 vs. &gt; 0) differences in ALPS_comb are statistically significant for all three cohorts (ADNI: <italic toggle="yes">p</italic> = 0.0082, DELCODE: <italic toggle="yes">p</italic> = 0.0244, ActiGlia: <italic toggle="yes">p</italic> = 0.0016), suggesting a meaningful association. In contrast, the MMSE (&lt; 27 vs. ≥ 27) comparisons show weaker or no significant differences, with only ActiGliA reaching significance (<italic toggle="yes">p</italic> = 0.0072), while ADNI (<italic toggle="yes">p</italic> = 0.1285) and DELCODE (<italic toggle="yes">p</italic> = 0.0742) do not. This suggests that ALPS_comb differences are more strongly linked to CDR status than MMSE classification (Fig. <xref rid="Fig9" ref-type="fig">9</xref>).</p><p id="Par44">
<fig id="Fig9" position="float" orientation="portrait"><label>Fig. 9</label><caption><p>Boxplots for ALPS_comb and clinical assessment measures (MMSE: low &lt; 27, high = &gt; 27 or CDR: low = 0, high &gt; 0)</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e2393" position="float" orientation="portrait" xlink:href="13195_2025_1707_Fig9_HTML.jpg"/></fig>
</p></sec></sec><sec id="Sec17"><title>Discussion</title><p id="Par45">The ALPS-Index has gained prominence as a tool for measuring the glymphatic system’s functionality in various neurodegenerative disorders, including Parkinson’s disease, frontotemporal dementia, amyotrophic lateral sclerosis, stroke, migraines, idiopathic normal pressure hydrocephalus, and traumatic brain injuries among others [<xref ref-type="bibr" rid="CR39">39</xref>–<xref ref-type="bibr" rid="CR44">44</xref>]. This study aimed to explore the association of the ALPS-Index with hallmarks of AD, such as cognitive decline and overall dementia severity, CSF biomarkers and markers of microvascular damage (WMH).</p><p id="Par46">The main results of our study were: (i) There was a significant group differences in ALPS indices between AD patients and HC across all cohorts, with AD patients showing lower ALPS indices. (ii) ALPS-Index was positively associated with Aβ42 and cognitive and clinical decline and (iii) WMH within a ROI is leading to lower ALPS indices. Our findings confirm earlier studies that have identified the ALPS-Index as a viable marker for disease progression and potentially for early detection of AD in very early stages, mild cognitive impairment, or even before the onset of symptoms. In a study by Zhong et al., AD patients showed significantly lower ALPS-Index compared to controls, and a decreased ALPS-Index with cognitive decline [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR45">45</xref>].</p><p id="Par47">Furthermore, we observed strong correlations between the ALPS-Index and CSF biomarkers, particularly Aβ42 and the Aβ42/Aβ40 ratio. Higher CSF Aβ42 levels consistently correlated with higher ALPS indices across the cohorts, supporting the hypothesis that glymphatic clearance mechanisms are closely tied to amyloid-beta metabolism. Notably, this is the first study to establish such a relationship with CSF biomarkers, highlighting its unique contribution to the field of AD research. Similarly, other studies show correlations between ALPS and extracellular perivascular space (ePVS), which suggest a shared pathology between impaired glymphatic function and AD-specific markers such as amyloid-beta aggregation, as observed in both PET scans and CSF samples [<xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR46">46</xref>, <xref ref-type="bibr" rid="CR47">47</xref>].</p><p id="Par48">While our analysis initially showed no significant differences in WMH volume or count between AD and HC groups within the ADNI cohort, a more detailed examination within the DELCODE and ActiGlia cohort revealed significant correlations between WMH count and ALPS indices. This suggests that WMH may impact the measurement of the ALPS-Index, possibly due to changes in bulk diffusivity caused by the WMH, though an association between AD pathology and cerebrovascular factors cannot be ruled out. It has been shown in several previous studies that WMH are correlated to glymphatic impairment and the higher the vascular damage the lower the ALPS-Index [<xref ref-type="bibr" rid="CR48">48</xref>–<xref ref-type="bibr" rid="CR50">50</xref>]. One study in particular highlighted an interesting L-shaped association of the DTI-ALPS-Index with the presence and severity of CSVD (cortical small vessel disease) measured by taking WMH into account [<xref ref-type="bibr" rid="CR50">50</xref>]. The graph could indicate a threshold level of glymphatic function beyond which WMH begin to significantly impact brain health. When ALPS-Index values are above this threshold, WMH values remain low and stable. However, once the ALPS-Index falls below this critical value, WMH values start to increase sharply. This suggests that a minimally functional glymphatic system might be sufficient to prevent or limit WMH, but any further decline leads to rapid deterioration. At lower levels of WMH, the vascular impairment might be mild and not significantly affect glymphatic function. However, with more extensive vascular damage (as WMH increases), there may be a critical point where glymphatic impairment becomes pronounced, leading to the observed decline in the ALPS-Index. This L-shaped association might be a reason to why especially smaller cohorts might not show too big of a correlation between ALPS and WMH. Another study was able to show how DTI-ALPS-Index partially mediated the association of Choroid plexus volume (CPv) with both WMH load and growth and how CPv was correlated with slower glymphatic clearance in the brain– again highlighting the close relationship between WMH, vascular health and the clearance of the brain done by the GS [<xref ref-type="bibr" rid="CR49">49</xref>].</p><p id="Par49">Specifically, there was a negative correlation between WMH in the ROI and ALPS, likely due to vascular impairments in these regions affecting measurements of diffusivity along the x-axis. These findings were significant in both the ADNI and DELCODE cohorts but not in ActiGliA, likely due to the small number of subjects with WMH in these specific ROIs (<italic toggle="yes">n</italic> = 4). Once we combined all three cohorts together and looked at correlation with age, sex, and group as confounding variables, we found significant negative correlations in all three ALPS indices, likely due to vascular impairments in these regions affecting measurements of diffusivity along the x-axis. This highlights the necessity of considering vascular damage when interpreting ALPS-Index changes, as such damage can mimic or obscure changes attributable to AD pathology.</p><p id="Par50">Crucially, our findings also revealed significant correlations between MMSE and CDR scores and the ALPS-Index across all three cohorts, indicating that glymphatic system impairment is associated with decline in cognitive performance and increased dementia severity. These findings are in line with several previous studies suggesting a correlation between ALPS-Index and cognitive decline in AD [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR27">27</xref>].</p><p id="Par51">The observed differences in ALPS indices between the left and right hemispheres suggest variations in diffusivity along perivascular spaces, potentially reflecting asymmetries in glymphatic system function. Recent studies have revealed asymmetry in the glymphatic system function between brain hemispheres, with observations of a leftward asymmetry in healthy adults. It is hypothesized that the glymphatic system may function as a separate system in the left and right hemispheres [<xref ref-type="bibr" rid="CR51">51</xref>]. Several factors could contribute to these hemispheric differences. Anatomical variations in the vascular and perivascular architecture between hemispheres may influence the efficiency of glymphatic clearance [<xref ref-type="bibr" rid="CR52">52</xref>]. Functional lateralization of the brain, particularly differences in neuronal activity or metabolic demands, could also play a role, as glymphatic function is closely tied to cerebrovascular dynamics and interstitial fluid flow. Furthermore, asymmetrical distribution of white matter hyperintensities or regional variations in AQP4 expression, which regulates fluid transport, might differentially affect glymphatic function. These findings underscore the need for further research to understand how hemispheric differences in glymphatic activity might contribute to or result from neurodegenerative processes like Alzheimer’s disease.</p><p id="Par52">While our study provides valuable insights into the importance of glymphatic impairment in AD, it is important to acknowledge several limitations that may affect the generalizability and interpretation of our findings. Potential for WMH to confound the ALPS-Index calculations remains a critical concern. The ALPS-Index is predicated on assessing changes in diffusivity along the x-axis, representing alterations in fluid dynamics within perivascular spaces—a key factor in AD pathology.</p><p id="Par53">One significant concern is that the ALPS index primarily measures predominant water diffusion along the perivascular space, yet it does not directly validate glymphatic system functionality. Moreover, this method lacks the ability to differentiate between water movement within or outside the perivascular space and cannot assess the direction of flow. This measurement can be confounded by the presence of vascular damage, such as that represented by WMH, which can similarly affect diffusivity metrics. Further research is essential to develop strategies that effectively differentiate between changes due to perivascular space alterations and those resulting from vascular damage. Additionally, variations in imaging techniques, resolution, and ROI placement impact the reproducibility and interpretation of the ALPS index. To our knowledge, this is the first study that incorporates WMH into the calculation of the ALPS-Index [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR53">53</xref>]. This study’s exclusion of individuals with pronounced WMH within the ROI was an attempt to address this issue; however, future studies should incorporate more comprehensive methodologies to mitigate such confounding factors. Our study’s scope was limited to early-stage AD cases, primarily within demographically homogeneous populations. Future studies should aim to include more diverse populations to enhance the representativeness and generalizability of the findings, and they should incorporate follow-up periods to assess the enduring effects of the variables studied. We were unable to control for all potential confounding variables, such as lifestyle factors and genetic predispositions, which might influence the results. Future studies should consider a broader range of confounding factors. The relatively small sample size for WMH in ROI may limit the statistical power to detect significant differences and relationships.</p><p id="Par54">Lastly, other studies also touched upon the role of inflammation, microglial activation, and reactive astrogliosis in impairing aquaporin-4 (AQP4), leading to discrepancies in CSF flow and accumulation of brain waste products such as Aβ and tau [<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR54">54</xref>–<xref ref-type="bibr" rid="CR56">56</xref>]. Extending this speculation, perhaps regional loss of AQP4 may explain subregion-dependent susceptibility to neurodegeneration by driving local interstitial fluid and protein stagnation increasing the risk of aggregation prone proteins. This inflammation might be a precursor to or a consequence of protein aggregation, suggesting a complex, possibly bidirectional relationship between neuroinflammation and neurodegeneration. The interplay between AQP4, neuroinflammation, and the glymphatic system may contribute to the progression of neurodegenerative processes [<xref ref-type="bibr" rid="CR57">57</xref>].</p><p id="Par55">While there are some similarities between our study and the work by Shu-Yi Huang et al., 2024 [<xref ref-type="bibr" rid="CR46">46</xref>], there are several significant differences that distinguish our research. The previous study primarily focuses on longitudinal cohorts and examines how ALPS might be used as a clinical marker to track disease progression or detect Alzheimer’s disease. In contrast, our study utilizes three distinct cohorts in a cross-sectional analysis to explore how ALPS correlates with WMH and other AD-specific biomarkers, with a particular focus on WMH found in the ROI.</p><p id="Par56">One of the key distinctions in our methodology is the use of WMH as a biomarker, specifically excluding participants with WMH in the ROI, allowing us to investigate the localized effects of WMH on ALPS. This aspect was not specifically addressed in the earlier study. Additionally, while the previous study utilized the PACC to measure cognitive function, we used MMSE and CDR, which are more commonly used in clinical settings and provide different insights into cognitive status in our cohort.</p><p id="Par57">Overall, our study aims to provide new insights into how WMH in the ROI influences ALPS and its potential to correlate with other Alzheimer’s disease biomarkers, offering a novel approach distinct from the longitudinal focus of the prior research.</p><p id="Par58">In conclusion, our findings underscore the potential of the ALPS-Index as a biomarker for Alzheimer’s Disease, albeit with considerations for the influence of WMH on its accuracy and reliability. The variations observed across cohorts highlight the complexity of AD pathology and the need for comprehensive approaches in biomarker development, including associative analyses beyond imaging, such as those offered by animal models, histological examinations, and other investigative methods. Further studies are needed to elucidate the role of cerebrovascular factors in AD and refine neuroimaging biomarkers for early diagnosis and disease monitoring, with a particular focus on cognitive implications in our aging population.</p></sec><sec id="Sec400" sec-type="supplementary-material"><title>Electronic supplementary material</title><p>Below is the link to the electronic supplementary material.</p><p>
<supplementary-material content-type="local-data" id="MOESM1" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="13195_2025_1707_MOESM1_ESM.docx" position="float" orientation="portrait"><caption><p>Supplementary Material 1</p></caption></media></supplementary-material>
</p></sec></body><back><fn-group><fn><p><bold>Publisher’s note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn><fn><p>Philine Marie Schirge and Robert Perneczky have contributed equally to this work.</p></fn></fn-group><ack><title>Acknowledgements</title><p>This study was supported by the German Center for Neurodegenerative Disorders (Deutsches Zentrum fürNeurodegenerative Erkrankungen), Hirnliga (Manfred-Strohscheer Stiftung), and the German Research Foundation (Deutsche Forschungsgemeinschaft) under Germany’s Excellence Strategy within the framework of the Munich Cluster for Systems Neurology (EXC 2145 SyNergy, ID 390857198). R.P. also receives support from the Davos Alzheimer’s Collaborative, the VERUM Foundation, the Robert-Vogel-Foundation, the National Institute for Health and Care Research (NIHR) Sheffield Biomedical Research Centre (NIHR203321), the University of Cambridge– Ludwig-Maximilians-University Munich Strategic Partnership within the framework of the German Excellence Initiative and Excellence Strategy and the European Commission under the Innovative Health Initiative program (project 101132356). ). A.R-R. receives funding from the IZKF Advanced Medical Scientist Program of Jena University Hospital. We thank the ADNI participants and staff for their support, dedication, and commitment. Data collection andsharing were funded by ADNI (NIH grant U01 AG024904) and Department of Defense (DOD) ADNI (DOD award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging and the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from AbbVie, Alzheimer’s Association, Alzheimer’s Drug Discovery Foundation, Araclon Biotech, BioClinica, Biogen, Bristol Myers Squibb, CereSpir, Cogstate, Eisai, Elan Pharmaceuticals, Eli Lilly and Company, EuroImmun, F. Hoffmann-La Roche and its affiliated company Genentech, Fujirebio, GE Healthcare, IXICO, Janssen Alzheimer Immunotherapy Research &amp; Development, Johnson &amp; Johnson Pharmaceutical Research &amp; Development, Lumosity, Lundbeck, Merck &amp; Co, Meso Scale Diagnostics, NeuroRx Research, Neurotrack Technologies, Novartis Pharmaceuticals Corporation, Pfizer, Piramal Imaging, Servier, Takeda Pharmaceutical Company, and Transition Therapeutics. The Canadian Institutes of Health Research provide funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer’s Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California. Open Access funding enabled and organized by Projekt DEAL. The authors thank Christian Haass, PhD for his support with the ActiGliA cohort. Consortium ContributionsDELCODE Study GroupThe DELCODE Study Group comprises investigators from multiple sites who have contributed to the design, data acquisition, or analysis of the DELCODE study. Specific authors listed in the main author list (Julian Hellmann-Regen10,11,12, Josef Priller10,14,15,16, Anja Schneider17,18, Frank Jessen17,19,20, Emrah Düzel21,22, Katharina Buerger4,23, Stefan Teipel24,25, Christoph Laske26,27, Oliver Peters10,13, Eike Spruth10,14, Klaus Fliessbach17,18, Ayda Rostamzadeh19, Wenzel Glanz21, Daniel Janowitz23, Ingo Kilimann24,25, Sebastian Sodenkamp26,28, Michael Ewers4,23) are also part of the DELCODE consortium.Alzheimer’s Disease Neuroimaging Initiative (ADNI)Data used in preparation of this article were obtained from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report. A complete listing of ADNI investigators can be found at: http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>Generation, preprocessing and analysis of mri data were planned and conducted by BSR, ALRR, PMS, RP, EE, MB. Data from neuropsychologic/neurocognitive assessments and NPT factor scores were generated and analyzed by SG, CK, PMS, RP and BSR. TT developed the ALPS Index. PMS, BSR, and RP utilized the index to perform the calculations and analysis. PMS, RP, ALRR and BSR contributed to the data analysis strategy and drafting of the manuscript. PMS and BSR wrote the main manuscript text and PMS prepared the figures. PMS, BSR and EE performed statistical analyses. The overall design, implementation, DELCODE methodological core central data management and data analyses, and collection of data for the DELCODE study at the different study sites were provided by RF, JHR, JP, AS, FJ, ED, KB, ST, CL, OP, ES, KF, AR, WG, DJ, IK, SS and ME. All authors reviewed the manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>Open Access funding enabled and organized by Projekt DEAL.</p><p>This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>No datasets were generated or analysed during the current study.</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par59">Each study was approved by the local ethics committee of the participating centers, including the ethics committee of LMU Munich (project numbers 17–755 and 17–569). Patients with early AD (subjective cognitive impairment, MCI and mild AD dementia) and age-matched cognitively normal controls were included after providing written informed consent in line with the declaration of Helsinki.</p></notes><notes id="FPar2"><title>DELCODE study group</title><p id="Par60">The DELCODE Study Group comprises investigators from multiple sites who have contributed to the design, data acquisition, or analysis of the DELCODE study. Specific authors listed in the main author list (Julian Hellmann-Regen<sup>10,11,12</sup>, Josef Priller<sup>10,14,15,16</sup>, Anja Schneider<sup>17,18</sup>, Frank Jessen<sup>17,19,20</sup>, Emrah Düzel<sup>21,22</sup>, Katharina Buerger<sup>4,23</sup>, Stefan Teipel<sup>24,25</sup>, Christoph Laske<sup>26,27</sup>, Oliver Peters<sup>10,13</sup>, Eike Spruth<sup>10,14</sup>, Klaus Fliessbach<sup>17,18</sup>, Ayda Rostamzadeh<sup>19</sup>, Wenzel Glanz<sup>21</sup>, Daniel Janowitz<sup>23</sup>, Ingo Kilimann<sup>24,25</sup>, Sebastian Sodenkamp<sup>26,28</sup>, Michael Ewers<sup>4,23</sup>) are also part of the DELCODE consortium.</p></notes><notes id="FPar3"><title>Alzheimer’s disease neuroimaging initiative (ADNI)</title><p id="Par61">Data used in preparation of this article were obtained from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report. A complete listing of ADNI investigators can be found at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf">http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf</ext-link>.</p></notes><notes id="FPar4"><title>Consent for publication</title><p id="Par62">Not applicable.</p></notes><notes id="FPar5" notes-type="COI-statement"><title>Competing interests</title><p id="Par63">The authors declare no competing interests.</p></notes><notes id="FPar6"><title>Disclosures</title><p id="Par64">The authors have nothing to disclose.</p></notes></notes><glossary><title>Abbreviations</title><def-list><def-item><term>AD</term><def><p id="Par65">Alzheimer‘s disease</p></def></def-item><def-item><term>Aβ</term><def><p id="Par66">amyloid beta</p></def></def-item><def-item><term>DTI-ALPS</term><def><p id="Par67">Diffusion tensor Imaging along perivascular spaces</p></def></def-item><def-item><term>HC</term><def><p id="Par68">healthy controls</p></def></def-item><def-item><term>CVD</term><def><p id="Par69">cerebrovascular disease</p></def></def-item><def-item><term>ADS</term><def><p id="Par70">Alzheimer’s disease subjects</p></def></def-item><def-item><term>WMH</term><def><p id="Par71">White matter hyperintensities</p></def></def-item><def-item><term>PVS</term><def><p id="Par72">Perivascular space</p></def></def-item><def-item><term>FLAIR</term><def><p id="Par73">fluid attenuated inversion recovery</p></def></def-item><def-item><term>LST</term><def><p id="Par74">lesion segmentation tool</p></def></def-item><def-item><term>ROI</term><def><p id="Par75">Region of interest</p></def></def-item><def-item><term>CSF</term><def><p id="Par76">cerebrospinal fluid</p></def></def-item><def-item><term>MMSE</term><def><p id="Par77">Mini Mental state examination</p></def></def-item><def-item><term>CDR</term><def><p id="Par78">clinical dementia rating</p></def></def-item><def-item><term>BBB</term><def><p id="Par79">Blood brain barrier</p></def></def-item><def-item><term>ISF</term><def><p id="Par80">interstitial fluid</p></def></def-item><def-item><term>FA</term><def><p id="Par81">fractional anisotropy</p></def></def-item><def-item><term>SD</term><def><p id="Par82">standard deviation</p></def></def-item><def-item><term>ALPS_comb</term><def><p id="Par83">left and right ALPS-Index combined</p></def></def-item><def-item><term>ALPS_R</term><def><p id="Par84">right ALPS-Index</p></def></def-item><def-item><term>ALPS_L</term><def><p id="Par85">left ALPS-Index</p></def></def-item><def-item><term>ePVS</term><def><p id="Par86">enlarged perivascular space</p></def></def-item><def-item><term>CSVD</term><def><p id="Par87">cortical small vessel disease</p></def></def-item><def-item><term>CPv</term><def><p id="Par88">choroid plexus volume</p></def></def-item><def-item><term>AQP4</term><def><p id="Par89">Aquaporin 4 channel</p></def></def-item><def-item><term>M/F</term><def><p id="Par90">male/female</p></def></def-item><def-item><term>TR</term><def><p id="Par91">repetition time</p></def></def-item><def-item><term>TE</term><def><p id="Par92">echo time</p></def></def-item><def-item><term>FoV</term><def><p id="Par93">field of view</p></def></def-item></def-list></glossary><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>DeTure</surname><given-names>MA</given-names></name><name name-style="western"><surname>Dickson</surname><given-names>DW</given-names></name></person-group><article-title>The neuropathological diagnosis of Alzheimer’s disease</article-title><source>Mol Neurodegener</source><year>2019</year><volume>14</volume><issue>1</issue><fpage>32</fpage><pub-id pub-id-type="doi">10.1186/s13024-019-0333-5</pub-id><pub-id pub-id-type="pmid">31375134</pub-id><pub-id pub-id-type="pmcid">PMC6679484</pub-id></element-citation><mixed-citation id="mc-CR1" publication-type="journal">DeTure MA, Dickson DW. The neuropathological diagnosis of Alzheimer’s disease. Mol Neurodegener. 2019;14(1):32.<pub-id pub-id-type="pmid">31375134</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13024-019-0333-5</pub-id><pub-id pub-id-type="pmcid">PMC6679484</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Harrington</surname><given-names>CR</given-names></name></person-group><article-title>The molecular pathology of Alzheimer’s disease</article-title><source>Neuroimaging Clin N Am</source><year>2012</year><volume>22</volume><issue>1</issue><fpage>11</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1016/j.nic.2011.11.003</pub-id><pub-id pub-id-type="pmid">22284730</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Harrington CR. The molecular pathology of Alzheimer’s disease. Neuroimaging Clin N Am. 2012;22(1):11–22. vii.<pub-id pub-id-type="pmid">22284730</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.nic.2011.11.003</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Selkoe</surname><given-names>DJ</given-names></name></person-group><article-title>Clearing the brain’s amyloid cobwebs</article-title><source>Neuron</source><year>2001</year><volume>32</volume><issue>2</issue><fpage>177</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1016/S0896-6273(01)00475-5</pub-id><pub-id pub-id-type="pmid">11683988</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Selkoe DJ. Clearing the brain’s amyloid cobwebs. Neuron. 2001;32(2):177–80.<pub-id pub-id-type="pmid">11683988</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0896-6273(01)00475-5</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kurz</surname><given-names>A</given-names></name><name name-style="western"><surname>Perneczky</surname><given-names>R</given-names></name></person-group><article-title>Amyloid clearance as a treatment target against Alzheimer’s disease</article-title><source>J Alzheimers Dis JAD</source><year>2011</year><volume>24</volume><issue>Suppl 2</issue><fpage>61</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.3233/JAD-2011-102139</pub-id><pub-id pub-id-type="pmid">21422524</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Kurz A, Perneczky R. Amyloid clearance as a treatment target against Alzheimer’s disease. J Alzheimers Dis JAD. 2011;24(Suppl 2):61–73.<pub-id pub-id-type="pmid">21422524</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-2011-102139</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nedergaard</surname><given-names>M</given-names></name></person-group><article-title>Neuroscience. Garbage truck of the brain</article-title><source>Science</source><year>2013</year><volume>340</volume><issue>6140</issue><fpage>1529</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1126/science.1240514</pub-id><pub-id pub-id-type="pmid">23812703</pub-id><pub-id pub-id-type="pmcid">PMC3749839</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Nedergaard M. Neuroscience. Garbage truck of the brain. Science. 2013;340(6140):1529–30.<pub-id pub-id-type="pmid">23812703</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.1240514</pub-id><pub-id pub-id-type="pmcid">PMC3749839</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eide</surname><given-names>PK</given-names></name><name name-style="western"><surname>Vatnehol</surname><given-names>SAS</given-names></name><name name-style="western"><surname>Emblem</surname><given-names>KE</given-names></name><name name-style="western"><surname>Ringstad</surname><given-names>G</given-names></name></person-group><article-title>Magnetic resonance imaging provides evidence of glymphatic drainage from human brain to cervical lymph nodes</article-title><source>Sci Rep</source><year>2018</year><volume>8</volume><issue>1</issue><fpage>7194</fpage><pub-id pub-id-type="doi">10.1038/s41598-018-25666-4</pub-id><pub-id pub-id-type="pmid">29740121</pub-id><pub-id pub-id-type="pmcid">PMC5940793</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Eide PK, Vatnehol SAS, Emblem KE, Ringstad G. Magnetic resonance imaging provides evidence of glymphatic drainage from human brain to cervical lymph nodes. Sci Rep. 2018;8(1):7194.<pub-id pub-id-type="pmid">29740121</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-018-25666-4</pub-id><pub-id pub-id-type="pmcid">PMC5940793</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iliff</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Wang</surname><given-names>M</given-names></name><name name-style="western"><surname>Liao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Plogg</surname><given-names>BA</given-names></name><name name-style="western"><surname>Peng</surname><given-names>W</given-names></name><name name-style="western"><surname>Gundersen</surname><given-names>GA</given-names></name><etal/></person-group><article-title>A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid Β</article-title><source>Sci Transl Med</source><year>2012</year><volume>4</volume><issue>147</issue><fpage>147ra111</fpage><pub-id pub-id-type="doi">10.1126/scitranslmed.3003748</pub-id><pub-id pub-id-type="pmid">22896675</pub-id><pub-id pub-id-type="pmcid">PMC3551275</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">Iliff JJ, Wang M, Liao Y, Plogg BA, Peng W, Gundersen GA, et al. A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid Β. Sci Transl Med. 2012;4(147):147ra111.<pub-id pub-id-type="pmid">22896675</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/scitranslmed.3003748</pub-id><pub-id pub-id-type="pmcid">PMC3551275</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nedergaard</surname><given-names>M</given-names></name><name name-style="western"><surname>Goldman</surname><given-names>SA</given-names></name></person-group><article-title>Glymphatic failure as a final common pathway to dementia</article-title><source>Science</source><year>2020</year><volume>370</volume><issue>6512</issue><fpage>50</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1126/science.abb8739</pub-id><pub-id pub-id-type="pmid">33004510</pub-id><pub-id pub-id-type="pmcid">PMC8186542</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Nedergaard M, Goldman SA. Glymphatic failure as a final common pathway to dementia. Science. 2020;370(6512):50–6.<pub-id pub-id-type="pmid">33004510</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.abb8739</pub-id><pub-id pub-id-type="pmcid">PMC8186542</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tarasoff-Conway</surname><given-names>JM</given-names></name><name name-style="western"><surname>Carare</surname><given-names>RO</given-names></name><name name-style="western"><surname>Osorio</surname><given-names>RS</given-names></name><name name-style="western"><surname>Glodzik</surname><given-names>L</given-names></name><name name-style="western"><surname>Butler</surname><given-names>T</given-names></name><name name-style="western"><surname>Fieremans</surname><given-names>E</given-names></name><etal/></person-group><article-title>Clearance systems in the brain-implications for alzheimer disease</article-title><source>Nat Rev Neurol</source><year>2015</year><volume>11</volume><issue>8</issue><fpage>457</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1038/nrneurol.2015.119</pub-id><pub-id pub-id-type="pmid">26195256</pub-id><pub-id pub-id-type="pmcid">PMC4694579</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Tarasoff-Conway JM, Carare RO, Osorio RS, Glodzik L, Butler T, Fieremans E, et al. Clearance systems in the brain-implications for alzheimer disease. Nat Rev Neurol. 2015;11(8):457–70.<pub-id pub-id-type="pmid">26195256</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrneurol.2015.119</pub-id><pub-id pub-id-type="pmcid">PMC4694579</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ringstad</surname><given-names>G</given-names></name><name name-style="western"><surname>Vatnehol</surname><given-names>SAS</given-names></name><name name-style="western"><surname>Eide</surname><given-names>PK</given-names></name></person-group><article-title>Glymphatic MRI in idiopathic normal pressure hydrocephalus</article-title><source>Brain J Neurol</source><year>2017</year><volume>140</volume><issue>10</issue><fpage>2691</fpage><lpage>705</lpage><pub-id pub-id-type="doi">10.1093/brain/awx191</pub-id><pub-id pub-id-type="pmcid">PMC5841149</pub-id><pub-id pub-id-type="pmid">28969373</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Ringstad G, Vatnehol SAS, Eide PK. Glymphatic MRI in idiopathic normal pressure hydrocephalus. Brain J Neurol. 2017;140(10):2691–705.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/awx191</pub-id><pub-id pub-id-type="pmcid">PMC5841149</pub-id><pub-id pub-id-type="pmid">28969373</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Taoka</surname><given-names>T</given-names></name><name name-style="western"><surname>Masutani</surname><given-names>Y</given-names></name><name name-style="western"><surname>Kawai</surname><given-names>H</given-names></name><name name-style="western"><surname>Nakane</surname><given-names>T</given-names></name><name name-style="western"><surname>Matsuoka</surname><given-names>K</given-names></name><name name-style="western"><surname>Yasuno</surname><given-names>F</given-names></name><etal/></person-group><article-title>Evaluation of glymphatic system activity with the diffusion MR technique: diffusion tensor image analysis along the perivascular space (DTI-ALPS) in Alzheimer’s disease cases</article-title><source>Jpn J Radiol</source><year>2017</year><volume>35</volume><issue>4</issue><fpage>172</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1007/s11604-017-0617-z</pub-id><pub-id pub-id-type="pmid">28197821</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Taoka T, Masutani Y, Kawai H, Nakane T, Matsuoka K, Yasuno F, et al. Evaluation of glymphatic system activity with the diffusion MR technique: diffusion tensor image analysis along the perivascular space (DTI-ALPS) in Alzheimer’s disease cases. Jpn J Radiol. 2017;35(4):172–8.<pub-id pub-id-type="pmid">28197821</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11604-017-0617-z</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carotenuto</surname><given-names>A</given-names></name><name name-style="western"><surname>Cacciaguerra</surname><given-names>L</given-names></name><name name-style="western"><surname>Pagani</surname><given-names>E</given-names></name><name name-style="western"><surname>Preziosa</surname><given-names>P</given-names></name><name name-style="western"><surname>Filippi</surname><given-names>M</given-names></name><name name-style="western"><surname>Rocca</surname><given-names>MA</given-names></name></person-group><article-title>Glymphatic system impairment in multiple sclerosis: relation with brain damage and disability</article-title><source>Brain J Neurol</source><year>2022</year><volume>145</volume><issue>8</issue><fpage>2785</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1093/brain/awab454</pub-id><pub-id pub-id-type="pmid">34919648</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Carotenuto A, Cacciaguerra L, Pagani E, Preziosa P, Filippi M, Rocca MA. Glymphatic system impairment in multiple sclerosis: relation with brain damage and disability. Brain J Neurol. 2022;145(8):2785–95.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/awab454</pub-id><pub-id pub-id-type="pmid">34919648</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kikuta</surname><given-names>J</given-names></name><name name-style="western"><surname>Kamagata</surname><given-names>K</given-names></name><name name-style="western"><surname>Takabayashi</surname><given-names>K</given-names></name><name name-style="western"><surname>Taoka</surname><given-names>T</given-names></name><name name-style="western"><surname>Yokota</surname><given-names>H</given-names></name><name name-style="western"><surname>Andica</surname><given-names>C</given-names></name><etal/></person-group><article-title>An investigation of water diffusivity changes along the perivascular space in elderly subjects with hypertension</article-title><source>AJNR Am J Neuroradiol</source><year>2022</year><volume>43</volume><issue>1</issue><fpage>48</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.3174/ajnr.A7334</pub-id><pub-id pub-id-type="pmid">34794943</pub-id><pub-id pub-id-type="pmcid">PMC8757561</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Kikuta J, Kamagata K, Takabayashi K, Taoka T, Yokota H, Andica C, et al. An investigation of water diffusivity changes along the perivascular space in elderly subjects with hypertension. AJNR Am J Neuroradiol. 2022;43(1):48–55.<pub-id pub-id-type="pmid">34794943</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3174/ajnr.A7334</pub-id><pub-id pub-id-type="pmcid">PMC8757561</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>W</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><name name-style="western"><surname>Gong</surname><given-names>X</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Z</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name><etal/></person-group><article-title>Glymphatic clearance function in patients with cerebral small vessel disease</article-title><source>NeuroImage</source><year>2021</year><volume>238</volume><fpage>118257</fpage><pub-id pub-id-type="doi">10.1016/j.neuroimage.2021.118257</pub-id><pub-id pub-id-type="pmid">34118396</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Zhang W, Zhou Y, Wang J, Gong X, Chen Z, Zhang X, et al. Glymphatic clearance function in patients with cerebral small vessel disease. NeuroImage. 2021;238:118257.<pub-id pub-id-type="pmid">34118396</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroimage.2021.118257</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Steward</surname><given-names>CE</given-names></name><name name-style="western"><surname>Venkatraman</surname><given-names>VK</given-names></name><name name-style="western"><surname>Lui</surname><given-names>E</given-names></name><name name-style="western"><surname>Malpas</surname><given-names>CB</given-names></name><name name-style="western"><surname>Ellis</surname><given-names>KA</given-names></name><name name-style="western"><surname>Cyarto</surname><given-names>EV</given-names></name><etal/></person-group><article-title>Assessment of the DTI-ALPS parameter along the perivascular space in older adults at risk of dementia</article-title><source>J Neuroimaging Off J Am Soc Neuroimaging</source><year>2021</year><volume>31</volume><issue>3</issue><fpage>569</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.1111/jon.12837</pub-id><pub-id pub-id-type="pmid">33556226</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Steward CE, Venkatraman VK, Lui E, Malpas CB, Ellis KA, Cyarto EV, et al. Assessment of the DTI-ALPS parameter along the perivascular space in older adults at risk of dementia. J Neuroimaging Off J Am Soc Neuroimaging. 2021;31(3):569–78.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jon.12837</pub-id><pub-id pub-id-type="pmid">33556226</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iadecola</surname><given-names>C</given-names></name></person-group><article-title>The overlap between neurodegenerative and vascular factors in the pathogenesis of dementia</article-title><source>Acta Neuropathol (Berl)</source><year>2010</year><volume>120</volume><issue>3</issue><fpage>287</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.1007/s00401-010-0718-6</pub-id><pub-id pub-id-type="pmid">20623294</pub-id><pub-id pub-id-type="pmcid">PMC3001188</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Iadecola C. The overlap between neurodegenerative and vascular factors in the pathogenesis of dementia. Acta Neuropathol (Berl). 2010;120(3):287–96.<pub-id pub-id-type="pmid">20623294</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00401-010-0718-6</pub-id><pub-id pub-id-type="pmcid">PMC3001188</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Santos</surname><given-names>CY</given-names></name><name name-style="western"><surname>Snyder</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Wu</surname><given-names>WC</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>M</given-names></name><name name-style="western"><surname>Echeverria</surname><given-names>A</given-names></name><name name-style="western"><surname>Alber</surname><given-names>J</given-names></name></person-group><article-title>Pathophysiologic relationship between Alzheimer’s disease, cerebrovascular disease, and cardiovascular risk: A review and synthesis</article-title><source>Alzheimers Dement Amst Neth</source><year>2017</year><volume>7</volume><fpage>69</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.1016/j.dadm.2017.01.005</pub-id><pub-id pub-id-type="pmcid">PMC5328683</pub-id><pub-id pub-id-type="pmid">28275702</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Santos CY, Snyder PJ, Wu WC, Zhang M, Echeverria A, Alber J. Pathophysiologic relationship between Alzheimer’s disease, cerebrovascular disease, and cardiovascular risk: A review and synthesis. Alzheimers Dement Amst Neth. 2017;7:69–87.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.dadm.2017.01.005</pub-id><pub-id pub-id-type="pmcid">PMC5328683</pub-id><pub-id pub-id-type="pmid">28275702</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kisler</surname><given-names>K</given-names></name><name name-style="western"><surname>Nelson</surname><given-names>AR</given-names></name><name name-style="western"><surname>Montagne</surname><given-names>A</given-names></name><name name-style="western"><surname>Zlokovic</surname><given-names>BV</given-names></name></person-group><article-title>Cerebral blood flow regulation and neurovascular dysfunction in alzheimer disease</article-title><source>Nat Rev Neurosci</source><year>2017</year><volume>18</volume><issue>7</issue><fpage>419</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1038/nrn.2017.48</pub-id><pub-id pub-id-type="pmid">28515434</pub-id><pub-id pub-id-type="pmcid">PMC5759779</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Kisler K, Nelson AR, Montagne A, Zlokovic BV. Cerebral blood flow regulation and neurovascular dysfunction in alzheimer disease. Nat Rev Neurosci. 2017;18(7):419–34.<pub-id pub-id-type="pmid">28515434</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrn.2017.48</pub-id><pub-id pub-id-type="pmcid">PMC5759779</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iadecola</surname><given-names>C</given-names></name></person-group><article-title>Neurovascular regulation in the normal brain and in Alzheimer’s disease</article-title><source>Nat Rev Neurosci</source><year>2004</year><volume>5</volume><issue>5</issue><fpage>347</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1038/nrn1387</pub-id><pub-id pub-id-type="pmid">15100718</pub-id></element-citation><mixed-citation id="mc-CR19" publication-type="journal">Iadecola C. Neurovascular regulation in the normal brain and in Alzheimer’s disease. Nat Rev Neurosci. 2004;5(5):347–60.<pub-id pub-id-type="pmid">15100718</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrn1387</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bennett</surname><given-names>RE</given-names></name><name name-style="western"><surname>Robbins</surname><given-names>AB</given-names></name><name name-style="western"><surname>Hu</surname><given-names>M</given-names></name><name name-style="western"><surname>Cao</surname><given-names>X</given-names></name><name name-style="western"><surname>Betensky</surname><given-names>RA</given-names></name><name name-style="western"><surname>Clark</surname><given-names>T</given-names></name><etal/></person-group><article-title>Tau induces blood vessel abnormalities and angiogenesis-related gene expression in P301L Transgenic mice and human Alzheimer’s disease</article-title><source>Proc Natl Acad Sci U S A</source><year>2018</year><volume>115</volume><issue>6</issue><fpage>E1289</fpage><lpage>98</lpage><pub-id pub-id-type="doi">10.1073/pnas.1710329115</pub-id><pub-id pub-id-type="pmid">29358399</pub-id><pub-id pub-id-type="pmcid">PMC5819390</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">Bennett RE, Robbins AB, Hu M, Cao X, Betensky RA, Clark T, et al. Tau induces blood vessel abnormalities and angiogenesis-related gene expression in P301L Transgenic mice and human Alzheimer’s disease. Proc Natl Acad Sci U S A. 2018;115(6):E1289–98.<pub-id pub-id-type="pmid">29358399</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.1710329115</pub-id><pub-id pub-id-type="pmcid">PMC5819390</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jagust</surname><given-names>WJ</given-names></name><name name-style="western"><surname>Seab</surname><given-names>JP</given-names></name><name name-style="western"><surname>Huesman</surname><given-names>RH</given-names></name><name name-style="western"><surname>Valk</surname><given-names>PE</given-names></name><name name-style="western"><surname>Mathis</surname><given-names>CA</given-names></name><name name-style="western"><surname>Reed</surname><given-names>BR</given-names></name><etal/></person-group><article-title>Diminished glucose transport in Alzheimer’s disease: dynamic PET studies</article-title><source>J Cereb Blood Flow Metab Off J Int Soc Cereb Blood Flow Metab</source><year>1991</year><volume>11</volume><issue>2</issue><fpage>323</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1038/jcbfm.1991.65</pub-id><pub-id pub-id-type="pmid">1997504</pub-id></element-citation><mixed-citation id="mc-CR21" publication-type="journal">Jagust WJ, Seab JP, Huesman RH, Valk PE, Mathis CA, Reed BR, et al. Diminished glucose transport in Alzheimer’s disease: dynamic PET studies. J Cereb Blood Flow Metab Off J Int Soc Cereb Blood Flow Metab. 1991;11(2):323–30.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/jcbfm.1991.65</pub-id><pub-id pub-id-type="pmid">1997504</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Starr</surname><given-names>JM</given-names></name><name name-style="western"><surname>Farrall</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Armitage</surname><given-names>P</given-names></name><name name-style="western"><surname>McGurn</surname><given-names>B</given-names></name><name name-style="western"><surname>Wardlaw</surname><given-names>J</given-names></name></person-group><article-title>Blood-brain barrier permeability in Alzheimer’s disease: a case-control MRI study</article-title><source>Psychiatry Res</source><year>2009</year><volume>171</volume><issue>3</issue><fpage>232</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1016/j.pscychresns.2008.04.003</pub-id><pub-id pub-id-type="pmid">19211227</pub-id></element-citation><mixed-citation id="mc-CR22" publication-type="journal">Starr JM, Farrall AJ, Armitage P, McGurn B, Wardlaw J. Blood-brain barrier permeability in Alzheimer’s disease: a case-control MRI study. Psychiatry Res. 2009;171(3):232–41.<pub-id pub-id-type="pmid">19211227</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.pscychresns.2008.04.003</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McAleese</surname><given-names>KE</given-names></name><name name-style="western"><surname>Walker</surname><given-names>L</given-names></name><name name-style="western"><surname>Graham</surname><given-names>S</given-names></name><name name-style="western"><surname>Moya</surname><given-names>ELJ</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>M</given-names></name><name name-style="western"><surname>Erskine</surname><given-names>D</given-names></name><etal/></person-group><article-title>Parietal white matter lesions in Alzheimer’s disease are associated with cortical neurodegenerative pathology, but not with small vessel disease</article-title><source>Acta Neuropathol (Berl)</source><year>2017</year><volume>134</volume><issue>3</issue><fpage>459</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1007/s00401-017-1738-2</pub-id><pub-id pub-id-type="pmid">28638989</pub-id><pub-id pub-id-type="pmcid">PMC5563333</pub-id></element-citation><mixed-citation id="mc-CR23" publication-type="journal">McAleese KE, Walker L, Graham S, Moya ELJ, Johnson M, Erskine D, et al. Parietal white matter lesions in Alzheimer’s disease are associated with cortical neurodegenerative pathology, but not with small vessel disease. Acta Neuropathol (Berl). 2017;134(3):459–73.<pub-id pub-id-type="pmid">28638989</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00401-017-1738-2</pub-id><pub-id pub-id-type="pmcid">PMC5563333</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dean</surname><given-names>DC</given-names></name><name name-style="western"><surname>Hurley</surname><given-names>SA</given-names></name><name name-style="western"><surname>Kecskemeti</surname><given-names>SR</given-names></name><name name-style="western"><surname>O’Grady</surname><given-names>JP</given-names></name><name name-style="western"><surname>Canda</surname><given-names>C</given-names></name><name name-style="western"><surname>Davenport-Sis</surname><given-names>NJ</given-names></name><etal/></person-group><article-title>Association of amyloid pathology with Myelin alteration in preclinical alzheimer disease</article-title><source>JAMA Neurol</source><year>2017</year><volume>74</volume><issue>1</issue><fpage>41</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1001/jamaneurol.2016.3232</pub-id><pub-id pub-id-type="pmid">27842175</pub-id><pub-id pub-id-type="pmcid">PMC5195903</pub-id></element-citation><mixed-citation id="mc-CR24" publication-type="journal">Dean DC, Hurley SA, Kecskemeti SR, O’Grady JP, Canda C, Davenport-Sis NJ, et al. Association of amyloid pathology with Myelin alteration in preclinical alzheimer disease. JAMA Neurol. 2017;74(1):41–9.<pub-id pub-id-type="pmid">27842175</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamaneurol.2016.3232</pub-id><pub-id pub-id-type="pmcid">PMC5195903</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McAleese</surname><given-names>KE</given-names></name><name name-style="western"><surname>Firbank</surname><given-names>M</given-names></name><name name-style="western"><surname>Dey</surname><given-names>M</given-names></name><name name-style="western"><surname>Colloby</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Walker</surname><given-names>L</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>M</given-names></name><etal/></person-group><article-title>Cortical Tau load is associated with white matter hyperintensities</article-title><source>Acta Neuropathol Commun</source><year>2015</year><volume>3</volume><fpage>60</fpage><pub-id pub-id-type="doi">10.1186/s40478-015-0240-0</pub-id><pub-id pub-id-type="pmid">26419828</pub-id><pub-id pub-id-type="pmcid">PMC4589169</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">McAleese KE, Firbank M, Dey M, Colloby SJ, Walker L, Johnson M, et al. Cortical Tau load is associated with white matter hyperintensities. Acta Neuropathol Commun. 2015;3:60.<pub-id pub-id-type="pmid">26419828</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s40478-015-0240-0</pub-id><pub-id pub-id-type="pmcid">PMC4589169</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Prins</surname><given-names>ND</given-names></name><name name-style="western"><surname>Scheltens</surname><given-names>P</given-names></name></person-group><article-title>White matter hyperintensities, cognitive impairment and dementia: an update</article-title><source>Nat Rev Neurol</source><year>2015</year><volume>11</volume><issue>3</issue><fpage>157</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1038/nrneurol.2015.10</pub-id><pub-id pub-id-type="pmid">25686760</pub-id></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Prins ND, Scheltens P. White matter hyperintensities, cognitive impairment and dementia: an update. Nat Rev Neurol. 2015;11(3):157–65.<pub-id pub-id-type="pmid">25686760</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrneurol.2015.10</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhong</surname><given-names>J</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>J</given-names></name></person-group><article-title>A novel diffusion tensor image analysis along the perivascular space method to evaluate glymphatic alterations in Alzheimer’s disease</article-title><source>Annu Int Conf IEEE Eng Med Biol Soc IEEE Eng Med Biol Soc Annu Int Conf</source><year>2023</year><volume>2023</volume><fpage>1</fpage><lpage>4</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1109/EMBC40787.2023.10340315</pub-id><pub-id pub-id-type="pmid">38083428</pub-id></element-citation><mixed-citation id="mc-CR27" publication-type="journal">Zhong J, Wang L, Li Y, Jiang J. A novel diffusion tensor image analysis along the perivascular space method to evaluate glymphatic alterations in Alzheimer’s disease. Annu Int Conf IEEE Eng Med Biol Soc IEEE Eng Med Biol Soc Annu Int Conf. 2023;2023:1–4.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1109/EMBC40787.2023.10340315</pub-id><pub-id pub-id-type="pmid">38083428</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hsu</surname><given-names>JL</given-names></name><name name-style="western"><surname>Wei</surname><given-names>YC</given-names></name><name name-style="western"><surname>Toh</surname><given-names>CH</given-names></name><name name-style="western"><surname>Hsiao</surname><given-names>IT</given-names></name><name name-style="western"><surname>Lin</surname><given-names>KJ</given-names></name><name name-style="western"><surname>Yen</surname><given-names>TC</given-names></name><etal/></person-group><article-title>Magnetic resonance images implicate that glymphatic alterations mediate cognitive dysfunction in alzheimer disease</article-title><source>Ann Neurol</source><year>2023</year><volume>93</volume><issue>1</issue><fpage>164</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1002/ana.26516</pub-id><pub-id pub-id-type="pmid">36214568</pub-id><pub-id pub-id-type="pmcid">PMC10091747</pub-id></element-citation><mixed-citation id="mc-CR28" publication-type="journal">Hsu JL, Wei YC, Toh CH, Hsiao IT, Lin KJ, Yen TC, et al. Magnetic resonance images implicate that glymphatic alterations mediate cognitive dysfunction in alzheimer disease. Ann Neurol. 2023;93(1):164–74.<pub-id pub-id-type="pmid">36214568</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ana.26516</pub-id><pub-id pub-id-type="pmcid">PMC10091747</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hughes</surname><given-names>CP</given-names></name><name name-style="western"><surname>Berg</surname><given-names>L</given-names></name><name name-style="western"><surname>Danziger</surname><given-names>WL</given-names></name><name name-style="western"><surname>Coben</surname><given-names>LA</given-names></name><name name-style="western"><surname>Martin</surname><given-names>RL</given-names></name></person-group><article-title>A new clinical scale for the staging of dementia</article-title><source>Br J Psychiatry J Ment Sci</source><year>1982</year><volume>140</volume><fpage>566</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1192/bjp.140.6.566</pub-id><pub-id pub-id-type="pmid">7104545</pub-id></element-citation><mixed-citation id="mc-CR29" publication-type="journal">Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL. A new clinical scale for the staging of dementia. Br J Psychiatry J Ment Sci. 1982;140:566–72.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1192/bjp.140.6.566</pub-id><pub-id pub-id-type="pmid">7104545</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Morris</surname><given-names>JC</given-names></name></person-group><article-title>The clinical dementia rating (CDR): current version and scoring rules</article-title><source>Neurology</source><year>1993</year><volume>43</volume><issue>11</issue><fpage>2412</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1212/WNL.43.11.2412-a</pub-id><pub-id pub-id-type="pmid">8232972</pub-id></element-citation><mixed-citation id="mc-CR30" publication-type="journal">Morris JC. The clinical dementia rating (CDR): current version and scoring rules. Neurology. 1993;43(11):2412–4.<pub-id pub-id-type="pmid">8232972</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/wnl.43.11.2412-a</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rauchmann</surname><given-names>BS</given-names></name><name name-style="western"><surname>Brendel</surname><given-names>M</given-names></name><name name-style="western"><surname>Franzmeier</surname><given-names>N</given-names></name><name name-style="western"><surname>Trappmann</surname><given-names>L</given-names></name><name name-style="western"><surname>Zaganjori</surname><given-names>M</given-names></name><name name-style="western"><surname>Ersoezlue</surname><given-names>E</given-names></name><etal/></person-group><article-title>Microglial activation and connectivity in alzheimer disease and aging</article-title><source>Ann Neurol</source><year>2022</year><volume>92</volume><issue>5</issue><fpage>768</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1002/ana.26465</pub-id><pub-id pub-id-type="pmid">36053756</pub-id></element-citation><mixed-citation id="mc-CR31" publication-type="journal">Rauchmann BS, Brendel M, Franzmeier N, Trappmann L, Zaganjori M, Ersoezlue E, et al. Microglial activation and connectivity in alzheimer disease and aging. Ann Neurol. 2022;92(5):768–81.<pub-id pub-id-type="pmid">36053756</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ana.26465</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jessen</surname><given-names>F</given-names></name><name name-style="western"><surname>Spottke</surname><given-names>A</given-names></name><name name-style="western"><surname>Boecker</surname><given-names>H</given-names></name><name name-style="western"><surname>Brosseron</surname><given-names>F</given-names></name><name name-style="western"><surname>Buerger</surname><given-names>K</given-names></name><name name-style="western"><surname>Catak</surname><given-names>C</given-names></name><etal/></person-group><article-title>Design and first baseline data of the DZNE multicenter observational study on predementia Alzheimer’s disease (DELCODE)</article-title><source>Alzheimers Res Ther</source><year>2018</year><volume>10</volume><issue>1</issue><fpage>15</fpage><pub-id pub-id-type="doi">10.1186/s13195-017-0314-2</pub-id><pub-id pub-id-type="pmid">29415768</pub-id><pub-id pub-id-type="pmcid">PMC5802096</pub-id></element-citation><mixed-citation id="mc-CR32" publication-type="journal">Jessen F, Spottke A, Boecker H, Brosseron F, Buerger K, Catak C, et al. Design and first baseline data of the DZNE multicenter observational study on predementia Alzheimer’s disease (DELCODE). Alzheimers Res Ther. 2018;10(1):15.<pub-id pub-id-type="pmid">29415768</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13195-017-0314-2</pub-id><pub-id pub-id-type="pmcid">PMC5802096</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jessen</surname><given-names>F</given-names></name><name name-style="western"><surname>Wolfsgruber</surname><given-names>S</given-names></name><name name-style="western"><surname>Kleineindam</surname><given-names>L</given-names></name><name name-style="western"><surname>Spottke</surname><given-names>A</given-names></name><name name-style="western"><surname>Altenstein</surname><given-names>S</given-names></name><name name-style="western"><surname>Bartels</surname><given-names>C</given-names></name><etal/></person-group><article-title>Subjective cognitive decline and stage 2 of alzheimer disease in patients from memory centers</article-title><source>Alzheimers Dement J Alzheimers Assoc</source><year>2023</year><volume>19</volume><issue>2</issue><fpage>487</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.1002/alz.12674</pub-id><pub-id pub-id-type="pmid">35451563</pub-id></element-citation><mixed-citation id="mc-CR33" publication-type="journal">Jessen F, Wolfsgruber S, Kleineindam L, Spottke A, Altenstein S, Bartels C, et al. Subjective cognitive decline and stage 2 of alzheimer disease in patients from memory centers. Alzheimers Dement J Alzheimers Assoc. 2023;19(2):487–97.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.12674</pub-id><pub-id pub-id-type="pmid">35451563</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lewczuk</surname><given-names>P</given-names></name><name name-style="western"><surname>Matzen</surname><given-names>A</given-names></name><name name-style="western"><surname>Blennow</surname><given-names>K</given-names></name><name name-style="western"><surname>Parnetti</surname><given-names>L</given-names></name><name name-style="western"><surname>Molinuevo</surname><given-names>JL</given-names></name><name name-style="western"><surname>Eusebi</surname><given-names>P</given-names></name><etal/></person-group><article-title>Cerebrospinal fluid Aβ42/40 corresponds better than Aβ42 to amyloid PET in Alzheimer’s disease</article-title><source>J Alzheimers Dis JAD</source><year>2017</year><volume>55</volume><issue>2</issue><fpage>813</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.3233/JAD-160722</pub-id><pub-id pub-id-type="pmid">27792012</pub-id><pub-id pub-id-type="pmcid">PMC5147502</pub-id></element-citation><mixed-citation id="mc-CR34" publication-type="journal">Lewczuk P, Matzen A, Blennow K, Parnetti L, Molinuevo JL, Eusebi P, et al. Cerebrospinal fluid Aβ42/40 corresponds better than Aβ42 to amyloid PET in Alzheimer’s disease. J Alzheimers Dis JAD. 2017;55(2):813–22.<pub-id pub-id-type="pmid">27792012</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-160722</pub-id><pub-id pub-id-type="pmcid">PMC5147502</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Folstein</surname><given-names>MF</given-names></name><name name-style="western"><surname>Folstein</surname><given-names>SE</given-names></name><name name-style="western"><surname>McHugh</surname><given-names>PR</given-names></name></person-group><article-title>Mini-mental State. A practical method for grading the cognitive State.of patients for the clinician</article-title><source>J Psychiatr Res</source><year>1975</year><volume>12</volume><issue>3</issue><fpage>189</fpage><lpage>98</lpage><pub-id pub-id-type="doi">10.1016/0022-3956(75)90026-6</pub-id><pub-id pub-id-type="pmid">1202204</pub-id></element-citation><mixed-citation id="mc-CR35" publication-type="journal">Folstein MF, Folstein SE, McHugh PR. Mini-mental State. A practical method for grading the cognitive State.of patients for the clinician. J Psychiatr Res. 1975;12(3):189–98.<pub-id pub-id-type="pmid">1202204</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0022-3956(75)90026-6</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yokota</surname><given-names>H</given-names></name><name name-style="western"><surname>Vijayasarathi</surname><given-names>A</given-names></name><name name-style="western"><surname>Cekic</surname><given-names>M</given-names></name><name name-style="western"><surname>Hirata</surname><given-names>Y</given-names></name><name name-style="western"><surname>Linetsky</surname><given-names>M</given-names></name><name name-style="western"><surname>Ho</surname><given-names>M</given-names></name><etal/></person-group><article-title>Diagnostic performance of glymphatic system evaluation using diffusion tensor imaging in idiopathic normal pressure hydrocephalus and mimickers</article-title><source>Curr Gerontol Geriatr Res</source><year>2019</year><volume>2019</volume><fpage>5675014</fpage><pub-id pub-id-type="doi">10.1155/2019/5675014</pub-id><pub-id pub-id-type="pmid">31320896</pub-id><pub-id pub-id-type="pmcid">PMC6609364</pub-id></element-citation><mixed-citation id="mc-CR36" publication-type="journal">Yokota H, Vijayasarathi A, Cekic M, Hirata Y, Linetsky M, Ho M, et al. Diagnostic performance of glymphatic system evaluation using diffusion tensor imaging in idiopathic normal pressure hydrocephalus and mimickers. Curr Gerontol Geriatr Res. 2019;2019:5675014.<pub-id pub-id-type="pmid">31320896</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2019/5675014</pub-id><pub-id pub-id-type="pmcid">PMC6609364</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><mixed-citation publication-type="other">Schmidt P. Bayesian inference for structured additive regression models for large-scale problems with applications to medical imaging [Internet] [Text.PhDThesis]. Ludwig-Maximilians-Universität München; 2017 [cited 2024 Apr 21]. Available from: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://edoc.ub.uni-muenchen.de/20373/">https://edoc.ub.uni-muenchen.de/20373/</ext-link></mixed-citation></ref><ref id="CR38"><label>38.</label><mixed-citation publication-type="other">Schmidt P. An automated tool for detection of FLAIR-hyperintense white-matter lesions in Multiple Sclerosis - ScienceDirect [Internet]. 2012 [cited 2024 Apr 21]. Available from: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.sciencedirect.com/science/article/abs/pii/S1053811911013139">https://www.sciencedirect.com/science/article/abs/pii/S1053811911013139</ext-link><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroimage.2011.11.032</pub-id><pub-id pub-id-type="pmid">22119648</pub-id></mixed-citation></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Georgiopoulos</surname><given-names>C</given-names></name><name name-style="western"><surname>Tisell</surname><given-names>A</given-names></name><name name-style="western"><surname>Holmgren</surname><given-names>RT</given-names></name><name name-style="western"><surname>Eleftheriou</surname><given-names>A</given-names></name><name name-style="western"><surname>Rydja</surname><given-names>J</given-names></name><name name-style="western"><surname>Lundin</surname><given-names>F</given-names></name><etal/></person-group><article-title>Noninvasive assessment of glymphatic dysfunction in idiopathic normal pressure hydrocephalus with diffusion tensor imaging</article-title><source>J Neurosurg</source><year>2024</year><volume>140</volume><issue>3</issue><fpage>612</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.3171/2023.6.JNS23260</pub-id><pub-id pub-id-type="pmid">37724800</pub-id></element-citation><mixed-citation id="mc-CR39" publication-type="journal">Georgiopoulos C, Tisell A, Holmgren RT, Eleftheriou A, Rydja J, Lundin F, et al. Noninvasive assessment of glymphatic dysfunction in idiopathic normal pressure hydrocephalus with diffusion tensor imaging. J Neurosurg. 2024;140(3):612–20.<pub-id pub-id-type="pmid">37724800</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3171/2023.6.JNS23260</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>D</given-names></name><name name-style="western"><surname>Liu</surname><given-names>L</given-names></name><name name-style="western"><surname>Kong</surname><given-names>Y</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Z</given-names></name><name name-style="western"><surname>Rosa-Neto</surname><given-names>P</given-names></name><name name-style="western"><surname>Chen</surname><given-names>K</given-names></name><etal/></person-group><article-title>Regional glymphatic abnormality in behavioral variant frontotemporal dementia</article-title><source>Ann Neurol</source><year>2023</year><volume>94</volume><issue>3</issue><fpage>442</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1002/ana.26710</pub-id><pub-id pub-id-type="pmid">37243334</pub-id><pub-id pub-id-type="pmcid">PMC10657235</pub-id></element-citation><mixed-citation id="mc-CR40" publication-type="journal">Jiang D, Liu L, Kong Y, Chen Z, Rosa-Neto P, Chen K, et al. Regional glymphatic abnormality in behavioral variant frontotemporal dementia. Ann Neurol. 2023;94(3):442–56.<pub-id pub-id-type="pmid">37243334</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ana.26710</pub-id><pub-id pub-id-type="pmcid">PMC10657235</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>S</given-names></name><name name-style="western"><surname>Sun</surname><given-names>X</given-names></name><name name-style="western"><surname>Ren</surname><given-names>Q</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Dai</surname><given-names>T</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Glymphatic dysfunction in patients with early-stage amyotrophic lateral sclerosis</article-title><source>Brain J Neurol</source><year>2024</year><volume>147</volume><issue>1</issue><fpage>100</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1093/brain/awad274</pub-id><pub-id pub-id-type="pmid">37584389</pub-id></element-citation><mixed-citation id="mc-CR41" publication-type="journal">Liu S, Sun X, Ren Q, Chen Y, Dai T, Yang Y, et al. Glymphatic dysfunction in patients with early-stage amyotrophic lateral sclerosis. Brain J Neurol. 2024;147(1):100–8.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/awad274</pub-id><pub-id pub-id-type="pmid">37584389</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Park</surname><given-names>JH</given-names></name><name name-style="western"><surname>Bae</surname><given-names>YJ</given-names></name><name name-style="western"><surname>Kim</surname><given-names>JS</given-names></name><name name-style="western"><surname>Jung</surname><given-names>WS</given-names></name><name name-style="western"><surname>Choi</surname><given-names>JW</given-names></name><name name-style="western"><surname>Roh</surname><given-names>TH</given-names></name><etal/></person-group><article-title>Glymphatic system evaluation using diffusion tensor imaging in patients with traumatic brain injury</article-title><source>Neuroradiology</source><year>2023</year><volume>65</volume><issue>3</issue><fpage>551</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1007/s00234-022-03073-x</pub-id><pub-id pub-id-type="pmid">36274107</pub-id></element-citation><mixed-citation id="mc-CR42" publication-type="journal">Park JH, Bae YJ, Kim JS, Jung WS, Choi JW, Roh TH, et al. Glymphatic system evaluation using diffusion tensor imaging in patients with traumatic brain injury. Neuroradiology. 2023;65(3):551–7.<pub-id pub-id-type="pmid">36274107</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00234-022-03073-x</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shen</surname><given-names>T</given-names></name><name name-style="western"><surname>Yue</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ba</surname><given-names>F</given-names></name><name name-style="western"><surname>He</surname><given-names>T</given-names></name><name name-style="western"><surname>Tang</surname><given-names>X</given-names></name><name name-style="western"><surname>Hu</surname><given-names>X</given-names></name><etal/></person-group><article-title>Diffusion along perivascular spaces as marker for impairment of glymphatic system in Parkinson’s disease</article-title><source>NPJ Park Dis</source><year>2022</year><volume>8</volume><issue>1</issue><fpage>174</fpage><pub-id pub-id-type="doi">10.1038/s41531-022-00437-1</pub-id><pub-id pub-id-type="pmcid">PMC9772196</pub-id><pub-id pub-id-type="pmid">36543809</pub-id></element-citation><mixed-citation id="mc-CR43" publication-type="journal">Shen T, Yue Y, Ba F, He T, Tang X, Hu X, et al. Diffusion along perivascular spaces as marker for impairment of glymphatic system in Parkinson’s disease. NPJ Park Dis. 2022;8(1):174.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41531-022-00437-1</pub-id><pub-id pub-id-type="pmcid">PMC9772196</pub-id><pub-id pub-id-type="pmid">36543809</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vittorini</surname><given-names>MG</given-names></name><name name-style="western"><surname>Sahin</surname><given-names>A</given-names></name><name name-style="western"><surname>Trojan</surname><given-names>A</given-names></name><name name-style="western"><surname>Yusifli</surname><given-names>S</given-names></name><name name-style="western"><surname>Alashvili</surname><given-names>T</given-names></name><name name-style="western"><surname>Bonifácio</surname><given-names>GV</given-names></name><etal/></person-group><article-title>The glymphatic system in migraine and other headaches</article-title><source>J Headache Pain</source><year>2024</year><volume>25</volume><issue>1</issue><fpage>34</fpage><pub-id pub-id-type="doi">10.1186/s10194-024-01741-2</pub-id><pub-id pub-id-type="pmid">38462633</pub-id><pub-id pub-id-type="pmcid">PMC10926631</pub-id></element-citation><mixed-citation id="mc-CR44" publication-type="journal">Vittorini MG, Sahin A, Trojan A, Yusifli S, Alashvili T, Bonifácio GV, et al. The glymphatic system in migraine and other headaches. J Headache Pain. 2024;25(1):34.<pub-id pub-id-type="pmid">38462633</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s10194-024-01741-2</pub-id><pub-id pub-id-type="pmcid">PMC10926631</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhong</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name><name name-style="western"><surname>Xu</surname><given-names>H</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>X</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>J</given-names></name><etal/></person-group><article-title>Unlocking the enigma: unraveling multiple cognitive dysfunction linked to glymphatic impairment in early Alzheimer’s disease</article-title><source>Front Neurosci</source><year>2023</year><volume>17</volume><fpage>1222857</fpage><pub-id pub-id-type="doi">10.3389/fnins.2023.1222857</pub-id><pub-id pub-id-type="pmid">37547134</pub-id><pub-id pub-id-type="pmcid">PMC10400773</pub-id></element-citation><mixed-citation id="mc-CR45" publication-type="journal">Zhong J, Zhang X, Xu H, Zheng X, Wang L, Jiang J, et al. Unlocking the enigma: unraveling multiple cognitive dysfunction linked to glymphatic impairment in early Alzheimer’s disease. Front Neurosci. 2023;17:1222857.<pub-id pub-id-type="pmid">37547134</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnins.2023.1222857</pub-id><pub-id pub-id-type="pmcid">PMC10400773</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><mixed-citation publication-type="other">Huang SY, Zhang YR, Guo Y, Du J, Ren P, Wu BS et al. Glymphatic system dysfunction predicts amyloid deposition, neurodegeneration, and clinical progression in Alzheimer’s disease. Alzheimers Dement [Internet]. [cited 2024 Apr 16];n/a(n/a). Available from: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://onlinelibrary.wiley.com/doi/abs/">https://onlinelibrary.wiley.com/doi/abs/</ext-link>10.1002/alz.13789<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.13789</pub-id><pub-id pub-id-type="pmcid">PMC11095446</pub-id><pub-id pub-id-type="pmid">38501315</pub-id></mixed-citation></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Jiao</surname><given-names>B</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Shi</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Glymphatic system impairment in Alzheimer’s disease: associations with perivascular space volume and cognitive function</article-title><source>Eur Radiol</source><year>2024</year><volume>34</volume><issue>2</issue><fpage>1314</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1007/s00330-023-10122-3</pub-id><pub-id pub-id-type="pmid">37610441</pub-id></element-citation><mixed-citation id="mc-CR47" publication-type="journal">Zhang X, Wang Y, Jiao B, Wang Z, Shi J, Zhang Y, et al. Glymphatic system impairment in Alzheimer’s disease: associations with perivascular space volume and cognitive function. Eur Radiol. 2024;34(2):1314–23.<pub-id pub-id-type="pmid">37610441</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00330-023-10122-3</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hong</surname><given-names>H</given-names></name><name name-style="western"><surname>Hong</surname><given-names>L</given-names></name><name name-style="western"><surname>Luo</surname><given-names>X</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>Q</given-names></name><name name-style="western"><surname>Li</surname><given-names>K</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S</given-names></name><etal/></person-group><article-title>The relationship between amyloid pathology, cerebral small vessel disease, glymphatic dysfunction, and cognition: a study based on Alzheimer’s disease continuum participants</article-title><source>Alzheimers Res Ther</source><year>2024</year><volume>16</volume><issue>1</issue><fpage>43</fpage><pub-id pub-id-type="doi">10.1186/s13195-024-01407-w</pub-id><pub-id pub-id-type="pmid">38378607</pub-id><pub-id pub-id-type="pmcid">PMC10877805</pub-id></element-citation><mixed-citation id="mc-CR48" publication-type="journal">Hong H, Hong L, Luo X, Zeng Q, Li K, Wang S, et al. The relationship between amyloid pathology, cerebral small vessel disease, glymphatic dysfunction, and cognition: a study based on Alzheimer’s disease continuum participants. Alzheimers Res Ther. 2024;16(1):43.<pub-id pub-id-type="pmid">38378607</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13195-024-01407-w</pub-id><pub-id pub-id-type="pmcid">PMC10877805</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49.</label><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhong</surname><given-names>W</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>X</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>K</given-names></name><etal/></person-group><article-title>Choroid plexus enlargement exacerbates white matter hyperintensity growth through glymphatic impairment</article-title><source>Ann Neurol</source><year>2023</year><volume>94</volume><issue>1</issue><fpage>182</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1002/ana.26648</pub-id><pub-id pub-id-type="pmid">36971336</pub-id></element-citation><mixed-citation id="mc-CR49" publication-type="journal">Li Y, Zhou Y, Zhong W, Zhu X, Chen Y, Zhang K, et al. Choroid plexus enlargement exacerbates white matter hyperintensity growth through glymphatic impairment. Ann Neurol. 2023;94(1):182–95.<pub-id pub-id-type="pmid">36971336</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ana.26648</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR50"><label>50.</label><citation-alternatives><element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tian</surname><given-names>Y</given-names></name><name name-style="western"><surname>Cai</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y</given-names></name><name name-style="western"><surname>Jin</surname><given-names>A</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Impaired glymphatic system as evidenced by low diffusivity along perivascular spaces is associated with cerebral small vessel disease: a population-based study</article-title><source>Stroke Vasc Neurol</source><year>2023</year><volume>8</volume><issue>5</issue><fpage>413</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1136/svn-2022-002191</pub-id><pub-id pub-id-type="pmid">37045543</pub-id><pub-id pub-id-type="pmcid">PMC10647865</pub-id></element-citation><mixed-citation id="mc-CR50" publication-type="journal">Tian Y, Cai X, Zhou Y, Jin A, Wang S, Yang Y, et al. Impaired glymphatic system as evidenced by low diffusivity along perivascular spaces is associated with cerebral small vessel disease: a population-based study. Stroke Vasc Neurol. 2023;8(5):413–23.<pub-id pub-id-type="pmid">37045543</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/svn-2022-002191</pub-id><pub-id pub-id-type="pmcid">PMC10647865</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR51"><label>51.</label><citation-alternatives><element-citation id="ec-CR51" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Huang</surname><given-names>S</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>H</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Z</given-names></name><etal/></person-group><article-title>The asymmetry of glymphatic system dysfunction in patients with Temporal lobe epilepsy: A DTI-ALPS study</article-title><source>J Neuroradiol</source><year>2023</year><volume>50</volume><issue>6</issue><fpage>562</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1016/j.neurad.2023.05.009</pub-id><pub-id pub-id-type="pmid">37301366</pub-id></element-citation><mixed-citation id="mc-CR51" publication-type="journal">Zhao X, Zhou Y, Li Y, Huang S, Zhu H, Zhou Z, et al. The asymmetry of glymphatic system dysfunction in patients with Temporal lobe epilepsy: A DTI-ALPS study. J Neuroradiol. 2023;50(6):562–7.<pub-id pub-id-type="pmid">37301366</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neurad.2023.05.009</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR52"><label>52.</label><citation-alternatives><element-citation id="ec-CR52" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Duboc</surname><given-names>V</given-names></name><name name-style="western"><surname>Dufourcq</surname><given-names>P</given-names></name><name name-style="western"><surname>Blader</surname><given-names>P</given-names></name><name name-style="western"><surname>Roussigné</surname><given-names>M</given-names></name></person-group><article-title>Asymmetry of the brain: development and implications</article-title><source>Annu Rev Genet</source><year>2015</year><volume>49</volume><issue>49, 2015</issue><fpage>647</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1146/annurev-genet-112414-055322</pub-id><pub-id pub-id-type="pmid">26442849</pub-id></element-citation><mixed-citation id="mc-CR52" publication-type="journal">Duboc V, Dufourcq P, Blader P, Roussigné M. Asymmetry of the brain: development and implications. Annu Rev Genet. 2015;49(49, 2015):647–72.<pub-id pub-id-type="pmid">26442849</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1146/annurev-genet-112414-055322</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR53"><label>53.</label><citation-alternatives><element-citation id="ec-CR53" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hsiao</surname><given-names>WC</given-names></name><name name-style="western"><surname>Chang</surname><given-names>HI</given-names></name><name name-style="western"><surname>Hsu</surname><given-names>SW</given-names></name><name name-style="western"><surname>Lee</surname><given-names>CC</given-names></name><name name-style="western"><surname>Huang</surname><given-names>SH</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>CH</given-names></name><etal/></person-group><article-title>Association of cognition and brain reserve in aging and glymphatic function using diffusion tensor Image-along the perivascular space (DTI-ALPS)</article-title><source>Neuroscience</source><year>2023</year><volume>524</volume><fpage>11</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1016/j.neuroscience.2023.04.004</pub-id><pub-id pub-id-type="pmid">37030632</pub-id></element-citation><mixed-citation id="mc-CR53" publication-type="journal">Hsiao WC, Chang HI, Hsu SW, Lee CC, Huang SH, Cheng CH, et al. Association of cognition and brain reserve in aging and glymphatic function using diffusion tensor Image-along the perivascular space (DTI-ALPS). Neuroscience. 2023;524:11–20.<pub-id pub-id-type="pmid">37030632</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroscience.2023.04.004</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR54"><label>54.</label><citation-alternatives><element-citation id="ec-CR54" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hoshi</surname><given-names>A</given-names></name><name name-style="western"><surname>Yamamoto</surname><given-names>T</given-names></name><name name-style="western"><surname>Shimizu</surname><given-names>K</given-names></name><name name-style="western"><surname>Ugawa</surname><given-names>Y</given-names></name><name name-style="western"><surname>Nishizawa</surname><given-names>M</given-names></name><name name-style="western"><surname>Takahashi</surname><given-names>H</given-names></name><etal/></person-group><article-title>Characteristics of Aquaporin expression surrounding senile plaques and cerebral amyloid angiopathy in alzheimer disease</article-title><source>J Neuropathol Exp Neurol</source><year>2012</year><volume>71</volume><issue>8</issue><fpage>750</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1097/NEN.0b013e3182632566</pub-id><pub-id pub-id-type="pmid">22805778</pub-id></element-citation><mixed-citation id="mc-CR54" publication-type="journal">Hoshi A, Yamamoto T, Shimizu K, Ugawa Y, Nishizawa M, Takahashi H, et al. Characteristics of Aquaporin expression surrounding senile plaques and cerebral amyloid angiopathy in alzheimer disease. J Neuropathol Exp Neurol. 2012;71(8):750–9.<pub-id pub-id-type="pmid">22805778</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/NEN.0b013e3182632566</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR55"><label>55.</label><citation-alternatives><element-citation id="ec-CR55" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kecheliev</surname><given-names>V</given-names></name><name name-style="western"><surname>Boss</surname><given-names>L</given-names></name><name name-style="western"><surname>Maheshwari</surname><given-names>U</given-names></name><name name-style="western"><surname>Konietzko</surname><given-names>U</given-names></name><name name-style="western"><surname>Keller</surname><given-names>A</given-names></name><name name-style="western"><surname>Razansky</surname><given-names>D</given-names></name><etal/></person-group><article-title>Aquaporin 4 is differentially increased and dislocated in association with Tau and amyloid-beta</article-title><source>Life Sci</source><year>2023</year><volume>321</volume><fpage>121593</fpage><pub-id pub-id-type="doi">10.1016/j.lfs.2023.121593</pub-id><pub-id pub-id-type="pmid">36934970</pub-id></element-citation><mixed-citation id="mc-CR55" publication-type="journal">Kecheliev V, Boss L, Maheshwari U, Konietzko U, Keller A, Razansky D, et al. Aquaporin 4 is differentially increased and dislocated in association with Tau and amyloid-beta. Life Sci. 2023;321:121593.<pub-id pub-id-type="pmid">36934970</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.lfs.2023.121593</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR56"><label>56.</label><citation-alternatives><element-citation id="ec-CR56" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liddelow</surname><given-names>SA</given-names></name><name name-style="western"><surname>Guttenplan</surname><given-names>KA</given-names></name><name name-style="western"><surname>Clarke</surname><given-names>LE</given-names></name><name name-style="western"><surname>Bennett</surname><given-names>FC</given-names></name><name name-style="western"><surname>Bohlen</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Schirmer</surname><given-names>L</given-names></name><etal/></person-group><article-title>Neurotoxic reactive astrocytes are induced by activated microglia</article-title><source>Nature</source><year>2017</year><volume>541</volume><issue>7638</issue><fpage>481</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1038/nature21029</pub-id><pub-id pub-id-type="pmid">28099414</pub-id><pub-id pub-id-type="pmcid">PMC5404890</pub-id></element-citation><mixed-citation id="mc-CR56" publication-type="journal">Liddelow SA, Guttenplan KA, Clarke LE, Bennett FC, Bohlen CJ, Schirmer L, et al. Neurotoxic reactive astrocytes are induced by activated microglia. Nature. 2017;541(7638):481–7.<pub-id pub-id-type="pmid">28099414</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature21029</pub-id><pub-id pub-id-type="pmcid">PMC5404890</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR57"><label>57.</label><citation-alternatives><element-citation id="ec-CR57" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Szlufik</surname><given-names>S</given-names></name><name name-style="western"><surname>Kopeć</surname><given-names>K</given-names></name><name name-style="western"><surname>Szleszkowski</surname><given-names>S</given-names></name><name name-style="western"><surname>Koziorowski</surname><given-names>D</given-names></name></person-group><article-title>Glymphatic system pathology and neuroinflammation as two risk factors of neurodegeneration</article-title><source>Cells</source><year>2024</year><volume>13</volume><issue>3</issue><fpage>286</fpage><pub-id pub-id-type="doi">10.3390/cells13030286</pub-id><pub-id pub-id-type="pmid">38334678</pub-id><pub-id pub-id-type="pmcid">PMC10855155</pub-id></element-citation><mixed-citation id="mc-CR57" publication-type="journal">Szlufik S, Kopeć K, Szleszkowski S, Koziorowski D. Glymphatic system pathology and neuroinflammation as two risk factors of neurodegeneration. Cells. 2024;13(3):286.<pub-id pub-id-type="pmid">38334678</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cells13030286</pub-id><pub-id pub-id-type="pmcid">PMC10855155</pub-id></mixed-citation></citation-alternatives></ref></ref-list></back></article>